Caracterización clínica y genética de una muestra de pacientes colombianos con Epilepsia y análisis de posibles factores moleculares intervinientes en la respuesta a fármacos

132 páginas : gráficas

Autores:: Valbuena Mancipe, Luisa Fernanda
Rodríguez Estupiñán, Angie Tatiana
Triana Buitrago, Viviana Alexandra
Laguado González, Stephania

Tipo de recurso:: Trabajo de grado de pregrado

Fecha de publicación:: 2020

Institución:: Universidad de Ciencias Aplicadas y Ambientales U.D.C.A

Repositorio:: Repositorio Institucional UDCA

Idioma:: spa

id	RepoUDCA2_40a4757f8934c64f356f623590d0aeee
oai_identifier_str	oai:repository.udca.edu.co:11158/2919
network_acronym_str	RepoUDCA2
network_name_str	Repositorio Institucional UDCA
repository_id_str
dc.title.spa.fl_str_mv	Caracterización clínica y genética de una muestra de pacientes colombianos con Epilepsia y análisis de posibles factores moleculares intervinientes en la respuesta a fármacos
title	Caracterización clínica y genética de una muestra de pacientes colombianos con Epilepsia y análisis de posibles factores moleculares intervinientes en la respuesta a fármacos
spellingShingle	Caracterización clínica y genética de una muestra de pacientes colombianos con Epilepsia y análisis de posibles factores moleculares intervinientes en la respuesta a fármacos Biología Computacional Epilepsia Resistencia a Medicamentos Convulsiones
title_short	Caracterización clínica y genética de una muestra de pacientes colombianos con Epilepsia y análisis de posibles factores moleculares intervinientes en la respuesta a fármacos
title_full	Caracterización clínica y genética de una muestra de pacientes colombianos con Epilepsia y análisis de posibles factores moleculares intervinientes en la respuesta a fármacos
title_fullStr	Caracterización clínica y genética de una muestra de pacientes colombianos con Epilepsia y análisis de posibles factores moleculares intervinientes en la respuesta a fármacos
title_full_unstemmed	Caracterización clínica y genética de una muestra de pacientes colombianos con Epilepsia y análisis de posibles factores moleculares intervinientes en la respuesta a fármacos
title_sort	Caracterización clínica y genética de una muestra de pacientes colombianos con Epilepsia y análisis de posibles factores moleculares intervinientes en la respuesta a fármacos
dc.creator.fl_str_mv	Valbuena Mancipe, Luisa Fernanda Rodríguez Estupiñán, Angie Tatiana Triana Buitrago, Viviana Alexandra Laguado González, Stephania
dc.contributor.advisor.spa.fl_str_mv	Maradei Anaya, Silvia Juliana, dir.
dc.contributor.advisor.none.fl_str_mv	García Orjuela, Danilo Alejandro
dc.contributor.author.spa.fl_str_mv	Valbuena Mancipe, Luisa Fernanda Rodríguez Estupiñán, Angie Tatiana Triana Buitrago, Viviana Alexandra Laguado González, Stephania
dc.subject.lcsh.spa.fl_str_mv	Biología Computacional
topic	Biología Computacional Epilepsia Resistencia a Medicamentos Convulsiones
dc.subject.mesh.spa.fl_str_mv	Epilepsia Resistencia a Medicamentos Convulsiones
description	132 páginas : gráficas
publishDate	2020
dc.date.accessioned.spa.fl_str_mv	2020-03-17T14:00:36Z
dc.date.available.spa.fl_str_mv	2020-03-17T14:00:36Z
dc.date.issued.spa.fl_str_mv	2020
dc.type.spa.fl_str_mv	Trabajo de grado - Pregrado
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_7a1f
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/bachelorThesis
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.content.spa.fl_str_mv	Text
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/TP
format	http://purl.org/coar/resource_type/c_7a1f
status_str	publishedVersion
dc.identifier.uri.spa.fl_str_mv	https://repository.udca.edu.co/handle/11158/2919
dc.identifier.local.spa.fl_str_mv	MH001 V14c 2020 (205924)
url	https://repository.udca.edu.co/handle/11158/2919
identifier_str_mv	MH001 V14c 2020 (205924)
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	Organización Mundial de la Salud. Epilepsia. Trastornos Neurologicos: desafíos para la salud Pública. Ginebra. 2006; 62 -77 Organización Panamericana de la Salud, Organización mundial de la salud. Informe de la epilepsia en América Latina y el Caribe. Washington; 2013 Ministerio de Salud y Protección Social [sede web]. Epilepsia: mucho más que convulsions; 2017 [ acceso 18 de julio de 2018]. Boletin de Prensa No016 de 2017. Disponible en: https://www.minsalud.gov.co/Paginas/Epilepsia-mucho-mas-queconvulsiones.aspx Medina M, Kestel D, Acevedo C, Mesa T, Rodriguez J. Epilepsia en Latino America Experiencias (OPS 2016). 2016. Maradei-Anaya SJ, Espinosa E, Izquierdo Á, Velasco-Parra HM. Detection of subtelomeric rearrangements due to MLPA in paediatric patients with refractory epilepsy in Colombia: the role of the CHL1 gene in pharmacoresistance. Rev Neurol. 2013; 57(10):444-50. Medina Malo C. Aspectos Clínicos y Psicosociales. Epilepsia. Bogotá D.C: Editorial Medica Panamericana; 2004. p39–44 Schmidt D, Löscher W. New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr. 2009;9(2):47-52 Gall CM, Lynch G. Integrins, synaptic plasticity and epileptogenesis. Adv Exp Med Biol. 2004; 548:12-33. Maradei Anaya SJ. Análisis de los perfiles genómicos de pacientes colombianos con Epilepsia Refractaria [Tesis de Maestría] Universidad Nacional de Colombia. 2017 Maradei Anaya SJ. Detección de Rearreglos Subteloméricos por MLPA en Pacientes Pediátricos con Epilepsia Refractaria en tres centros de Referencia Nacional en Colombia [Tesis de Pregrado]. Universidad Nacional de Colombia: 2013. Megiddo I, Colson A, Chisholm D, Dua T, Nandi A. Laxminarayan R Health and economic benefits of public financing of epilepsy treatment in India: An agentbased simulation model. Epilepsia. 2016; 57(3):464-474 Algahtani H, Al-Hakami F Al-Shehri M, Shirah B, Al-Qahtani MH, Abdulkareem AA, Naseer MI. A very rare form of autosomal dominant progressive myoclonus epilepsy caused by a novel variant in the PRICKLE1 gene. Seizure. 2019; 69: 133-139 STRING. [Internet]. [Consultado 6 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=1qszWqvtLbTk Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005; 46(2): 224-235. Pellegrino F. Trastornos del movimiento IV. Movimientos involuntarios originados en el Sistema Nervioso Central. Revista Argentina de Neurología Veterinaria. 2019;7(2):1 Genetics Home Reference. Chromosomes & mtDNA. [Internet]. [Consultado 3 Oct 2019]. Disponible en: https://ghr.nlm.nih.gov/chromosome Gastaut H. Classification of the epilepsies: proposal for the international classification. Epilepsia 1969; 10: 514 – 521. Paolone G, Falcicchia C, Lovisari F, Kokaia M, Bell WJ, Fradet T, Barbieri M, Wahlberg LU, Emerich DF, Simonato M. Long-Term, Targeted Delivery of GDNF from Encapsulated Cells Is Neuroprotective and Reduces Seizures in the Pilocarpine Model of Epilepsy. J Neurosci. 2019; 39(11):2144-2156 Barro-Soria R. Epilepsy-associated mutations in the voltage sensor of KCNQ3 affect voltage dependence of channel opening. J Gen Physiol. 2019;151(2):247-257 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-424. Jovel CAE, Pardo CM, Moreno CM, Vergara J, Hedmont D, Mejía FES. Perfil demográfico y social de la epilepsia en una población vulnerable y de bajos recursos económicos en Bogotá, Colombia. Neurología: Publicación oficial de la Sociedad Española de Neurología 2016; 31(8): 528-534 Tarcas Yacubian EM, Contreas Caicedo G, Rios Pohl L.Tratamiento Farmacológico de las Epilepsias. Sao Paulo. ALADE; 2014. 35-51 Asconapé JJ. Epilepsy: new drug targets and neurostimulation. Neurol Clin. 2013; 31(3): 785-798. Gavatha M, Ioannou I, Papavasiliou AS. Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav. 2011; 20(4): 691-693. Feenstra B, Pasternak B, Geller F, Carstensen L, Wang T, Huang F, Eitson JL, Hollegaard MV, Svanström H, Vestergaard M, Hougaard DM, Schoggins JW, Jan LY, Melbye M, Hviid A. Common variants associated with general and MMR vaccine-related febrile seizures. Nat Genet. 2014;46(12):1274-1282 Ministerio de Salud y Protección Social. Guía de Práctica Clínica sobre el Diagnóstico y Tratamiento de la Epilepsia. Organización Panamericana de la Salud;2014 Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013; 9: 883- 892. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross H, Elger C, Enegel J, Forsgren L, Jacqueline A, Glynn M, Hesdorffer D, Lee I, Mathem G, Moshé S, Perucca E, Scheffer E, Tomson T, Watanabe M, Wiebe S. Definición Clínica Practica de la epilepsia. Epilepsia 2014; 55 (4): 475-485 STRING. [Internet]. [Consultado 4 Nov 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=z6KMfceDySvU Genetics Home Reference. GLRA1 gene. [Internet]. [Consultado 30 Oct 2019]. Disponible en: https://ghr.nlm.nih.gov/gene/GLRA1 Eckle VE, Shcheglovitov A, Vitko I, Dey D, Choo Yap C, Winckler B, Perez Reyes E. Mechanisms by which a CACNA1H mutation in epilepsy patients increases seizure susceptibility. J Physiol. 2014; 592.4: 795–809. Núñez E, Bonilla Y, Varela D. Actualización de métodos diagnósticos en el Complejo de Esclerosis Tuberosa. Rev Mex Neuroci. 2016; 17 (4): 86-95. Dixit AB, Banerjee J, Srivastava A, Tripathi M, Sarkar C, Kakkar A, Jain M, Chandra PS RNA-seq analysis of hippocampal tissues reveals novel candidate genes for drug refractory epilepsy in patients with MTLE-HS. Genomics. 2016;107(5):178-88 STRING. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=ulsA1j1oSBWX) Sharma S, Carlson S, Puttachary S, Sarkar S, Showman L, Putra M, Kanthasamy AG, Thippeswamy T. Role of the Fyn-PKCδ signaling in SE-induced neuroinflammation and epileptogenesis in experimental models of temporal lobe epilepsy. Neurobiol Dis. 2018; 110:102-121 Skluzacek JV, Watts KP, Parsy O, Wical B, Camfield P. Síndrome de Dravet y asociaciones de padres: la experiencia de la Liga IDEA con condiciones comórbidas, mortalidad, manejo, adaptación y duelo. Epilepsia. 2011; 52: 95-101 Jensen AA, Mosbacher J, Elg S, Lingenhoehl K, Lohmann T, Johansen TN, et al. The anticonvulsant gabapentin (neurontin) does not act through gammaaminobutyric acid-B receptors. Mol Pharmacol 2002; 61(6):1377-1384 Ip JPK, Mellios N, Sur M. Rett syndrome: insights into genetic, molecular and circuit mechanisms. Nat Rev Neurosci. 2018;19(6): 368-382 Hoda JC, Wanischeck M, Bertrand D, Steinlein OK. Pleiotropic functional effects of the first epilepsy-associated mutation in the human CHRNA2 gene. FEBS Lett. 2009; OMIM. PROTEIN O-MANNOSYLTRANSFERASE 1; POMT1. [Internet]. [Consultado 3 Nov 2019]. Disponible en: https://www.omim.org/entry/607423?search=POMT1&highlight=pomt1 Liu J, Tong L, Song S, Niu Y, Li J, Wu X, Zhang J, Zai CC, Luo F, Wu J, Li H, Wong AHC, Sun R, Liu F, Li B. Novel and de novo mutations in pediatric refractory epilepsy. Movel Brain. 2018;11(1): 48-66 Judson MC, Wallace ML, Sidorov MS, Burette AC, Gu B, van Woerden GM, King IF, Han JE, Zylka MJ, Elgersma Y, Weinberg RJ, Philpot BD. GABAergic neuron-specific loss of Ube3a causes Angelman syndrome-like EEG abnormalities and enhances seizure susceptibility. Neuron. 2016; 90(1): 56-69 Bai B, Guo YR, Zhang YH, Jin CC, Zhang JM, Chen H, Zhu BS. Novel DOCK7 mutations in a Chinese patient with early infantile epileptic encephalopathy 23. Chin Med J (Engl). 2019; 132(5): 600-603 Reyes Botero G, Uribe C. Epilepsia refractaria. Acta de Neurología Colombiana. 2010; 26: 34 - 36 Glass HC. Neonatal seizures: advances in mechanisms and management. Clin Perinatol. 2014; 41(1):177-190 Chen ZR, Liu DT, Meng H, Liu L, Bian WJ, Liu XR, Zhu WW, He Y, Wang J, Tang B, Su T, Yi YH. Homozygous missense TPP1 mutation associated with mild late infantile neuronal ceroid lipofuscinosis and the genotype-phenotype correlation. Seizure.2019; 68:180-185 Gallek MJ, Skoch J, Ansay T, Behbahani M, Mount D, Manziello A, Witte M, Bernas M, Labiner DM, Weinand MECortical gene expression: prognostic value for seizure outcome following temporal lobectomy and amygdalohippocampectomy. Neurogenetics. 2016;17(4):211-218. Stödberg T, McTague A, Ruiz AJ, Hirata H, Zhen J, Long P, Farabella I, Meyer E, Kawahara A, Vassallo G, Stivaros SM, Bjursell MK, Stranneheim H, Tigerschiöld S, Persson B, Bangash I, Das K, Hughes D, Lesko N, Lundeberg J, Scott RC, Poduri A, Scheffer IE, Smith H, Gissen P, Schorge S, Reith ME, Topf M, Kullmann DM, Harvey RJ, Wedell A, Kurian MA. Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures. Nat Commun.2015;6:8038 Mirza N, Vasieva O, Marson AG, Pirmohamed M. Exploring the genomic basis of pharmacoresistance in epilepsy: an integrative analysis of large-scale gene expression profiling studies on brain tissue from epilepsy surgery. Hum Mol Genet. 2011; 20(22):4381-4394 Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010; 51(4): 676-685 Licourt Otero D, Cala Hernández O, Travieso Téllez A, Orraca Castillo M. La heterogeneidad genética en la epilepsia: presentación de familias. Revista de Ciencias Médicas de Pinar del Río. 2015; 19(1):141-150. Organización Panamericana de la Salud, Organización Mundial de la Salud. Estrategia y plan de acción sobre la epilepsia. 51. º Consejo Directivo de la OPS, 63.ª sesión del Comité Regional de la OMS para las Américas.2011. Huisman S, Mulder PA, Redeker E, Bader I, Bisgaard AM, Brooks A, Cereda A, Cinca C, Clark D, Cormier-Daire V, Deardorff MA, Diderich K, Elting M, van Essen A, Fitz Patrick D, Gervasini C, Gillessen-Kaesbach G, Girisha KM, Hilhorst-Hofstee Y, Hopman S, Horn D, Isrie M, Jansen S, Jespersgaard C, Kaiser FJ, Kaur M, Kleefstra T, . Krantz ID, Lakeman P, Landlust, A, Lessel D. Phenotypes and genotypes in individuals with SMC1A variants. American Journal of Medical Genetics; 173(8): 2108–2125. Bencurova P, Baloun J, Musilova K, Radova L, Tichy B, Pail M, Zeman M, Brichtova E, Hermanova M, Pospisilova S, Mraz M, Brazdil M. MicroRNA and mesial temporal lobe epilepsy with hippocampal sclerosis: Whole miRNome profiling of human hippocampus. Epilepsia. 2017; 58(10):1782-1793 INVITAE [internet]. [consultado 3 Nov 2019]. Disponible en: https://www.invitae.com/en/physician/genes/20112/#info-panel-gene_function Splawski S, Yoo DS, Stotz SC, Cherry A, Clapham DE, Keating MT. CACNA1H Mutations in Autism Spectrum Disorders. THE JOURNAL OF BIOLOGICAL CHEMISTRY. 2006; 281 (31): 22085-22091 STRING. [Internet]. [Consultado 2 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=kGfzkLat0Woi Valles-Ortega J, Duran J, Garcia-Rocha M, Bosch C, Saez I, Pujadas L, Serafin A, Cañas X, Soriano E, Delgado-García JM, Gruart A, Guinovart JJ. Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease. EMBO Mol Med. 2011;3(11):667-681 Chen T, Giri M, Xia Z, Subedi YD, Li Y. Genetic and epigenetic mechanisms of epilepsy: a review. Neuropsychiatr Dis Treat. 2017; 13:1841-1859 Jin H, Jin-Jing HL, Zhen Su H, Wang DN, Lin Y, Wang N, Chen WJ. Identification of a Novel Homozygous Splice-Site Mutation in SCARB2 that Causes Progressive Myoclonus Epilepsy with or without Renal Failure.Chin Med J (Engl). 2018; 131(13):1575-1583 Roach PJ. Glycogen phosphorylation and Lafora disease. Mol ASpects Med. 2015; 46:78-84 Méndez Ayala A, Nariño D, Rosselli D. Burden of epilepsy in Colombia. Neuroepidemiology. 2015; 44(3): 144-148 Lopes Cendes I, Oliveria Ribero PA. Aspectos genéticos de las epilepsias: una visión actualizada. Rev Med Clinica los Condes. 2013;24(6):909-914 Rogawski MA, Gryder D, Castaneda D, Yonekawa W, Banks MK, Lia H. GluR5 kainate receptors, seizures, and the amygdala. Ann N Y Acad Sci. 2003; 985:150- 162. Rozman C, Cardellach F. Medicina Interna. 18 th. Ed. Madrid: EL SERVIER; 2016:1330-1347 Balestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. Neuroscience Letters. 2018; 667: 27- 39 Löscher W. How to Explain Multidrug Resistance in Epilepsy? Epilepsy Currents. 2005; 5(3):107-112 ILAE. EPILEPSY SYNDROMES. [Internet]. [Consultado 9 Nov 2019]. Disponible en: https://www.epilepsydiagnosis.org/syndrome/epilepsy-syndromegroupoverview.html STRING. [Internet]. [Consultado 5 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=ddQnrNPJpBOS STRING. [Internet]. [Consultado 5 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=l1b3ohYenpQz IVAME. Pruebas genéticas - Epilepsia nocturna del lóbulo frontal autosómica dominante (Autosomal dominant nocturnal frontal lobe epilepsy - ADNFLE-) – Genes CHRNA2, CHRNA4 y CHRNB2. – IVAMI. [internet] [consultado 4 Nov 2019] Disponible en: https://www.ivami.com/es/pruebas-geneticasmutaciones-de-genes-humanos-enfermedades-neoplasias-yfarmacogenetica/1371-pruebas-geneticas-epilepsia-nocturna-del-lobulo-frontal-autosomica-dominante-autosomal-dominant-nocturnal-frontal-lobe-epilepsy-adnflegenes-i-chrna2-chrna4-i-y-i-chrnb2 Makrythanasis P, Kato M, Zaki M, Saitsu H, Nakamura K, Santoni F. Pathogenic Variants in PIGG Cause Intellectual Disability with Seizures and Hypotonia. The American Journal of Human Genetics. 2016;98(4):615-626. Hosford DA, Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia. 1997; 38(4):408-414. Nazish HR, Ali N, Ullah S.The possible effect of SCN1A and SCN2A genetic variants on carbamazepine response among Khyber Pakhtunkhwa epileptic patients, Pakistan. Ther Clin Risk Manag. 2018;14: 2305-2313 Espinosa C, Sobrino FE. Farmacorresistencia en epilepsia. Conceptos clínicos y neurobiológicos. Neurología; 2015: 385 395. Liu Y, Guo Y, Liu P, Li F, Yang C, Song J, Hu J, Xin D, Chen Z. A case of Pitt-Hopkins Syndrome with de novo mutation in TCF4: Clinical features and treatment for epilepsy. IntJ Dev Neurosci. 2018; 67:51-54 Goldensohn ES, Porter RJ, Schwartzkroin PA. The American Epilepsy Society: an historic perspective on 50 years of advances in research. Epilepsia. 1997; 38(1):124-150. Ortiz L, Tabak N. Farmacogenómica en la práctica clínica. Rev Med Clin Condes. 2012; 23(5): 616-621. León Sarmiento FE. Estudio neuroepidemiológico nacional (EPINEURO) colombiano. Revista Panamericana de Salud Pública. 2003; 14(2):104-111. Paciorkowski AR, McDaniel SS, Jansen LA, Tully H, Tuttle E, Ghoneim DH, Tupal S, Gunter SA, Vasta V, Zhang Q, Tran T, Liu YB, Ozelius LJ, Brashear A, Sweadner KJ, Dobyns WB, Hahn S. Novel mutations in ATP1A3 associated with catastrophic early life epilepsy, episodic prolonged apnea, and postnatal microcephaly. Epilepsia. 2015; 56(3):422-430 OMIM. MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 7; SMAD7. [Internet]. [Consultado 2 Nov 2019]. Disponible en: https://www.omim.org/entry/602932?search=SMAD7&highlight=smad7 Schubert-Bast S, Rosenow F, Klein KM, Reif PS, Kieslich M, Strzelczyk A. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspective. Epilepsy Behav. 2019; 91:94-98. Marson, Anthony G, Al-Kharusi, Asya M, Alwaidh, Muna, Appleton Richard, Baker, Gus A,Chadwick. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007; 369(9566):1016-1026 Liu J, Schenker M, Ghiasvand S, Berdichevsky Y. Kinase Inhibitors with Antiepileptic Properties Identified with a Novel in Vitro Screening Platform. Int J Mol Sci. 2019;20(10) Tanaka AJ, Cho MT, Millan F, Juusola J, Retterer K, Joshi C, Niyazov D, Garnica A, Gratz E, Deardorff M, Wilkins A, Ortiz-Gonzalez X, Mathews K, Panzer K, Brilstra E, van Gassen KL, Volker-Touw CM, van Binsbergen E, Sobreira N, Hamosh A, McKnight D, Monaghan KG, Chung WK. Mutations in SPATA5 Are Associated with Microcephaly, Intellectual Disability, Seizures, and Hearing Loss. Am J Hum Genet. 2015; 97(3): 457.464 National Center for Advancing Translational Sciences. Hiperekplexia hereditaria. [Internet]. [Consultado 30 Oct 2019]. Disponible en: https://rarediseases.info.nih.gov/espanol/12005/hiperekplexiahereditaria/cases/66561 Ortega Moreno L, Giráldez BG, Verdú A, García Campos O, Sánchez Martín G, Serratosa JM, Guerrero López R. Nueva mutación en el gen STXBP1 en un paciente con síndrome de Ohtahara no lesional. Neurologia. 2016; 31(8): 523-527 STRING. [Internet]. [Consultado 30 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=7B88K6sTJMrY Hardies K, Cai Y, Jardel C, Jansen AC, Cao M, May P, Djémié T, Hachon Le Camus C, Keymolen K, Deconinck T, Bhambhani V, Long C, Sajan SA, Helbig KL; AR working group of the EuroEPINOMICS RES Consortium, Suls A, Balling R, Helbig I, De Jonghe P, Depienne C, De Camilli P, Weckhuysen S. Loss of SYNJ1 dual phosphatase activity leads to early onset refractory seizures and progressive neurological decline. Brain. 2016; 139(9):2420-2430 Sell K, Storch K, Hahn G, Lee-Kirsch MA, Ramantani G, Jackson S, Neilson D, von der Hagen M, Hehr U, Hehr U, Smitka M. Variable clinical course in acute necrotizing encephalopathy and identification of a novel RANBP2 mutation. Brain&Development. 2016: 38(8): 777-780 Vidaurre J. Síndromes epilépticos genéticos. Pediátr Panamá. 2017; 46 (2): 68 STRING. [Internet]. [Consultado 2 Nov 2019]. https://stringdb.org/cgi/network.pl?taskId=rOMfYUeidfAc Balestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. Neurosci Lett. 2018; 667: 27-39. Izquierdo AY. Crisis convulsivas. Concepto, clasificación y etiología. Emergencias: Revista de la Sociedad Española de Medicina de Urgencias y Emergencias. 2005; 17(5):1068-1073. Rossetti AO, Jeckelmann S, Novy J, Roth P, Weller M, Stupp R. Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro-oncology 2014; 16(4):584-588. Niday Z, Hawkins VE, Soh H, Mulkey DK, Tzingounis AV. EpilepsyAssociated KCNQ2 Channels Regulate Multiple Intrinsic Properties of Layer 2/3 Pyramidal Neurons. J Neurosci. 2017;37(3):576-586 Silbergleit R, Lowenstein D, Durkalski V, Conwit R. Lessons from the RAMPART study--and which is the best route of administration of benzodiazepines in status epilepticus. Epilepsia. 2013; 54 Suppl 6:74-77 Koemans TS, Kleefstra T, Chubak MC, Stone MH, Reijnders MRF, de Munnik S, Willemsen MH, Fenckova M, Stumpel CTRM, Bok LA, Sifuentes Saenz M, Byerly KA, Baughn LB, Stegmann APA, Pfundt R, Zhou H, van Bokhoven H, Schenck A, Kramer JM. Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intelectual disability and autism spectrum disorder. PLoS Genet. 2017;13(10) Scott DF. The discovery of anti-epileptic drugs. J Hist Neurosci.1992;1(2):111-118. Lu Z, Reddy MV, Liu J, Kalichava A, Liu J, Zhang L, Chen F, Wang Y, Holthauzen LM, White MA, Seshadrinathan S, Zhong X, Ren G, Rudenko G. Molecular Architecture of Contactin-associated Protein-like 2 (CNTNAP2) and Its Interaction with Contactin 2 (CNTN2). J Biol Chem. 2016;291(46):24133-24147 STRING. [Internet]. [Consultado 2 Nov 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=OE9wU0lV0paL Mingarro Castillo MM, Carmona de la Morena J, Latre Martínez P, Aras Portilla LM. Síndrome de Dravet. Rev Clin Med Fam. 2014; 7 (2): 134 -136 STRING. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=AnkpHPOhkou6 Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 2001; 21(8):904-919. UniProt. UniProtKB - P78352 (DLG4_HUMAN). [Internet]. [Consultado 2 Nov 2019]. Disponible en: https://www.uniprot.org/uniprot/P78352 Hosford DA, Clark S, Cao Z, Wilson WA, Lin FH, Morrisett RA, et al. The role of GABAB receptor activation in absence seizures of lethargic (lh/lh) mice. Science.1992; 257(5068):398-401. STRING. [Internet]. [Consultado 4 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=1ziRpo3Vx8nS Kuersten M, Tacke M, Gerstl L, Hoelz H, Stülpnagel CV, Borggraefe I. Antiepileptic therapy approaches in KCNQ2 related epilepsy: A systematic review. Eur J Med Genet. 2019; S1769-7212(18)30663-3. Arzimanoglou AA, Dumas C, Ghirardi L. Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. French Neurologists Sabril Study Group. Seizure 1997; 6(3):225-231. Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des. 2004; 10(12):1295-1312. Fry AE, Rees E, Thompson R, Mantripragada K, Blake P, Jones G, Morgan S, Jose S, Mugalaasi H, Archer H, McCann E, Clarke A, Taylor C, Davies S, Gibbon F, Te Water Naude J, Hartley L, Thomas G, White C, Natarajan J, Thomas RH, Drew C, Chung SK, Rees MI, Holmans P, Owen MJ, Kirov G, Pilz DT, Kerr MP. Pathogenic copy number variants and SCN1A mutations in patients with intellectual disability and childhood-onset epilepsy. BMC Med Genet. 2016; 17(1):34 Wright AG, Demyanenko GP, Powell A, Schachner M, Enriquez-Barreto L, Tran TS, Polleux F, Maness PF. Close homolog of L1 and neuropilin 1 mediate guidance of thalamocortical axons at the ventral telencephalon. J Neurosci. 2007; 27(50):13667-13679. Bisulli F, Muccioli L, d'Orsi G, Canafoglia L, Freri E, Licchetta L, Mostacci B, Riguzzi P, Pondrelli F, Avolio C, Martino T, Michelucci R, Tinuper P. Treatment with metformin in twelve patients with Lafora disease. Orphanet J Rare Dis. 2019;14(1):149. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel J. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46(4): 470-472 STRING. [Internet]. [Consultado 5 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=7oQo0Tl0gF1W Andreyeva A, Leshchyns'ka I, Knepper M, Betzel C, Redecke L, Sytnyk V, Schachner M. CHL1 is a selective organizar of the presynaptic machinery chaperoning the SNARE complex. PLoS One. 2010; 5(8):e12018 Serrano Barrera OR. Bioinformática: una brecha en la formación en el Sistema Nacional de Salud. Revista Cubana de Educación Media Superior; 26(1): 121-135 Hermann BP, Seidenberg M, Dow C, Jones J, Rutecki P, Bhattacharya A. Cognitive prognosis in chronic temporal lobe epilepsy. Ann Neurol. 2006; 60(1):80- 87. Dyment DA, Smith AC, Humphreys P, Schwartzentruber J, Beaulieu CL; FORGE Canada Consortium, Bulman DE, Majewski J, Woulfe J, Michaud J, Boycott KM. Homozygous nonsense mutation in SYNJ1 associated with intractable epilepsy and tau pathology. Neurobiol Aging. 2015;36(2);1222e1-1222e5 Kong Q, Min X, Sun R, Gao J, Liang R, Li L, Chu X. Effects of pharmacological treatments on hippocampal NCAM1 and ERK2 expression in epileptic rats with cognitive dysfunction. Oncol Lett. 2016;12(3):1783-1791 Ikemoto S, Hamano SI, Hirata Y, Matsuura R, Koichihara R. Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years. Seizure. 2019; S1059-1311(19):30136-0 Tijssen MA, Rees M. Hyperekplexia. GeneReviews. 2007. Oguni H, Nishikawa A, Satoa Y, Otania Y, Itoa S, Nagataa S, Katob M, Hamanakac K, Miyatake S, Matsumotoc N. A missense variant of SMC1A causes periodic pharmaco-resistant cluster seizures similar to PCDH19-related epilepsy. Epilepsy Research. 2019; 15: 106149 Bakir-Gungor B, Baykan B, Ugur İseri S, Tuncer FN, Sezerman OU. Identifying SNP targeted pathways in partial epilepsies with genome-wide association study data. Epilepsy Res. 2013; 105(1-2):92-102. Forsgren L, Hauser WA, Olafsson E, Sander, JS, Sillanpää M, Tomson T. Mortality of epilepsy in developed countries: a review. Epilepsia. 2005; 46 (11):18-27. Capovilla G, Beccaria F, Beghi E, Minicucci F, Sartori S, Vecchi M. Treatment of convulsive status epilepticus in childhood: recommendations of the Italian League Against Epilepsy. Epilepsia. 2013; 54 Suppl 7:23-34 Perrault I, Hamdan FF, Rio M, Capo-Chichi JM, Boddaert N, Décarie JC, Maranda B, Nabbout R, Sylvain M, Lortie A, Roux PP, Rossignol E, Gérard X, Barcia G, Berquin P, Munnich A, Rouleau GA, Kaplan J, Rozet JM, Michaud JL. Mutations in DOCK7 in individuals with epileptic encephalopathy and cortical blindness. Am J Hum Genet. 2014;94(6):891-897 Yelam A, Nagarajan E, Chuquilin M, Govindarajan R. Leucoencephalopathy with brain stem and spinal cord involvement and lactate elevation: a novel mutation in the DARS2 gene. BMJ Case Rep. 2019;12(1) Gastaut H, Naquet R, Poire R, Tassinari CA. TREATMENT OF STATUS EPILEPTICUS WITH DIAZEPAM (VALIUM). Epilepsia 1965; 6:167-182 García Morales I. Limitaciones en el tratamiento de la Epilepsia. Neurología. 2016;31(1):3-8 Anwar A, Saleem S, Patel UK, Arumaithurai K, Malik P. Síndrome de Dravet: una visión general. Cureus. 2019; 11 (6): e5006. Cendes F, Theodore WH, H. Brinkmann BH, Sulc V, Cascino GD. Neuroimaging of epilepsy. Handb Clin Neurol. 2016; 136: 985–1014. STRING. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=LwWuyKVegPwT Burneo JG, Tellez-Zenteno J, Wiebe S. Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence. Epilepsy. 2006; 66(1-3):63-74. Nakamura K, Osaka H, Murakami Y, Anzai R, Nishiyama K, Kodera H, Nakashima M, Tsurusaki Y, Miyake N, Kinoshita T, Matsumoto N, Saitsu H. PIGO mutations in intractable epilepsy and severe developmental delay with mild elevation of alkaline phosphatase levels. Epilepsia. 2014; 55(2): 13-17 Gu B, Carstens KE, Judson MC, Dalton KA, Rougié M, Clark EP, Dudek SM, Philpot BD. Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice. J Clin Invest; 129(1): 163-168 Scherpenzeel MV, Timal S, Rymen D, HoischenA, Wuhrer M , Hipgrave-Ederveen A, Grunewald S, Peanne R, Saada A, Edvardson S, Grønborg S, Ruijter G, Kattentidt-Mouravieva A, Moritz Brum J, Freckmann ML, Tomkins S, Jalan A, Prochazkova D, Ondruskova N, Hansikova H, Willemsen MA, Hensbergen PJ, Matthijs G, Wevers RA, Veltman JA, Morava E, Lefeber DJ. Diagnostic serum glycosylation profile in patients with intellectual disability as a result of MAN1B1 deficiency. Brain. 2014; 137: 1030–1038 van Diepen L, Buettner FFR, Hoffmann D, Thiesler CT, von Bohlen Und Halbach O, von Bohlen Und Halbach V, Jensen LR, Steinemann D, Edvardson S, Elpeleg O, Schambach A, Gerardy-Schahn R, Kuss AW. A patient-specific induced pluripotent stem cell model for West syndrome caused by ST3GAL3 deficiency. Eur J Hum Genet. 2018; 26(12):1773-1783 Bode A, Lynch JW. The impact of human hyperekplexia mutations on glycine receptor structure and function. Mol Brain. 2014; 7:2 Nguyen TT, Murakami Y, Sheridan E, Ehresmann S, Rousseau J, St-Denis A, Chai G, Ajeawung NF, Fairbrother L, Reimschisel T, Bateman A, Berry-Kravis E, Xia F, Tardif J, Parry DA, Logan CV, Diggle C, Bennett CP, Hattingh L, Rosenfeld JA, Perry MS, Parker MJ, Le Deist F, Zaki MS, Ignatius E, Isohanni P, Lönnqvist T, Carroll CJ, Johnson CA, Gleeson JG, Kinoshita T, CampeauPM. Mutations in GPAA1, Encoding a GPI Transamidase Complex Protein, Cause Dev elopmental Delay, Epilepsy, Cerebellar Atrophy, and Osteopenia. Am J Hum Genet. 2017; 101(5):856-865 Irintchev A, Koch M, Needham LK, Maness P, Schachner M. Impairment of sensorimotor gating in mice deficient in the cell adhesion molecule L1 or its close homologue, CHL1. Brain Res. 2004; 1029(1):131- 134. Villamizar Schiller I, Espinosa García E. Factores de Riesgo para Epilepsia después de una Primera Crisis no Provocada en la Edad Pediátrica en el Hospital Militar Central (2005-2008). 2010 Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BA. Lafora disease - from pathogenesis to treatment strategies. Nat Rev Neurol. 2018;14(10):606-617 Löscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver ways out of the current dilemma. Epilepsia 2011; 52(4):657-678 Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41 (1):3-9 Baulac S. mTOR signaling pathway genes in focal epilepsy. 2016. Prog Brain Res; 226: 61-79 Patrizio A, Renner M, Pizzarelli R, Triller A, Specht CG. Alpha subunitdependent glycine receptor clustering and regulation of synaptic receptor numbers. Sci Rep. 2017; 7: 10899 Veeramah KR, Johnstone L, Karafet TM, Wolf D, Sprissler R, Salogiannis J, Barth-Maron A, Greenberg ME, Stuhlmann T, Weinert S, Jentsch TJ, Pazzi M, Restifo LL, Talwar D, Erickson RP, Hammer MF. Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. Epilepsia. 2013: 54(7); 1270-1281 Puusepp S, Kovacs-Nagy R, Alhaddad B, Braunisch M, Hoffmann GF, Kotzaeridou U, Lichvarova L, Liiv M, Makowski C, Mandel M, Meitinger T, Pajusalu S, Rodenburg RJ, Safiulina D, Strom TM, Talvik I, Vaarmann A, Wilson C, Kaasik A, Haack TB, Õunap K. Compound heterozygous SPATA5 variants in four families and functional studies of SPATA5 deficiency. Eur J Hum Genet. 2018;26(3):407- 419 López González FJ, Rodríguez Osorio X, Gil-Nagel Rein A, Carreño Martínez M, Serratosa Fernández J, Villanueva Haba V. Epilepsia resistente a fármacos. Concepto y alternativas terapéuticas. Neurología. 2015; 30(7): 439-446 Herring BE, Nicoll RA. Long-Term Potentiation: From CaMKII to AMPA Receptor Trafficking. Annu Rev Physiol. 2016; 78:351-365 Gene Cards. CHL1 gene. [Internet]. [Consultado 27 Feb 2017]. Disponible en: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CHL1 Citraro R, Leo A, Santoro M, D'agostino G, Constanti A, Russo E. Role of histone deacetylases (HDACs) in epilepsy and epileptogenesis. Curr Pharm Des. 2017;23(37):5546-5562 Saldaña AM, Sánchez J, Márquez DD. Farmacogenética y metabolismo de fármacos antiepilépticos: implicación de variantes genéticas en citocromos P450. Neurología.com. 2018. 50(9). Núñez E, Bonilla Y, Varela D. Actualización de métodos diagnósticos en el Complejo de Esclerosis Tuberosa. Rev Mex Neuroci. 2016; 17 (4): 86-95. McCallum AP, Gallek MJ, Ramey W, Manziello A, Witte MH, Bernas MJ, Labiner DM, Weinand ME. Cortical gene expression correlates of temporal lobe epileptogenicity. Pathophysiology. 2016;23(3):181-90. Glauser TA, Holland K, O'Brien VP, Keddache M, Martin LJ, Clark PO, Cnaan A, Dlugos D, Hirtz DG, Shinnar S, Grabowski G. Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy. Ann Neurol. 2017;81(3):444-453 Panayiotopoulos CP. A Clinical Guide to Epileptic Syndromes and their Treatment .2da ed. Springer; 2010. p 91-134 Koene LMC van Grondelle SE, Proietti Onori M, Wallaard I, Kooijman NHRM, van Oort A, Schreiber J, Elgersma Y. Effects of antiepileptic drugs in a new TSC/mTOR-dependent epilepsy mouse model. Ann Clin Transl Neurol. 2019;6(7):1273-1291 McDaniel SS, Wong M. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. Neurosci Lett. 2011; 497(3):231- 139 Klepper J. Glucose transporter deficiency syndrome (GLUT1DS) and the ketogenic diet. Epilepsia. 2008;49(8):46-49 Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S1, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58(4):512-521 Dey A, Kang X, Qiu J, Du Y, Jiang J. Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside. Trends Pharmacol Sci. 2016;37(6):463-484 Santillán Garzón S, Álvarez D, Buades C, Romera-López A, Pérez-Cabornero L, Valero-Hervás D, et al. DIAGNÓSTICO MOLECULAR DE ENFERMEDADES GENÉTICAS: DEL DIAGNÓSTICO GENÉTICO AL DIAGNÓSTICO GENÓMICO CON LA SECUENCIACIÓN MASIVA. Rev Med Clin Condes. 2015; 26(4): 458-469 OMIM. DISCOS GRANDES ANÁLISIS MAGUK 3 PROTEÍNA; DLG3. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://www.omim.org/entry/300189 Ben-Shalom R, Keeshen CM, Berrios KN, An JY, Sanders SJ, Bender KJ. Opposing Effects on NaV1.2 Function Underlie Differences Between SCN2A Variants Observed in Individuals With Autism Spectrum Disorder or Infantile Seizures. Biol Psychiatry. 2017; 82(3): 224-232 Démurger F, Ichkou A, Mougou-Zerelli S, Le Merrer M, Goudefroye G, Delezoide AL, Quélin C, Manouvrier S, Baujat G, Fradin M, Pasquier L, Megarbané A, Faivre L, Baumann C, Nampoothiri S, Roume J, Isidor B, Lacombe D, Delrue MA, Mercier S, Philip N, Schaefer E, Holder M, Krause A, Laffargue F, Sinico M, Amram D, André G, Liquier A, Rossi M, Amiel J, Giuliano F, Boute O, DieuxCoeslier A, Jacquemont ML, Afenjar A, Van Maldergem L, Lackmy-Port-Lis M, Vincent-Delorme C, Chauvet ML, Cormier-Daire V, Devisme L, Geneviève D, Munnich A, Viot G, Raoul O, Romana S, Gonzales M, Encha-Razavi F, Odent S, Vekemans M, Attie-Bitach T New insights into genotype-phenotype correlation for GLI3 mutations. Eur J Hum Genet. 2015; 23(1): 92-102 Yurchenco PD, McKee KK, Reinhard JR, Ruegg MA. Laminin-defcient muscular dystrophy: Molecular pathogenesis and structural repair strategies. Matrix Biol. 2018: 174-187 Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51(6): 1069- 1077. Hartman AL, Rubenstein JE, Kossoff EH. Intermittent fasting: a "new" historical strategy for controlling seizures? Epilepsy. 2013; 104(3):275 Alexopoulos A. Pharmacoresistant epilepsy: Definition and explanation. Epileptology. 2013; 1: 38–42. Genetics Home Reference. SPATA5 gene. [Internet]. [Consultado 30 Oct 2019]. Disponible en: https://ghr.nlm.nih.gov/gene/SPATA5 STRING. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=BxMbc92rLHq6 Dominges F, Köning E, Schwienbacher C, Volpato CB, Picard A, Cantaloni C, Mascalzoni D, Lackner P, Heimbach A, Hoffmann P, Stanzial F, Hicks S, Parmeggiani L, Benedicenti F, Pellegrin S, Casara G, Prmastaller P. Compound heterozygous SZT2 mutations in two siblings with early-onset epilepsy, intellectual disability and macrocephaly. Seizure.2019; 66: 81-85 Blanco Lago R. Estudio en la cohorte española de pacientes con síndrome de Wolf Hirschhorn: análisis de la epilepsia en el síndrome y correlación genotipofenotipo. Universidad de Oviedo. 2016. Ojima T, Shibita E, Saito S, Toyoda M, Nakajima H, Yamazaki-Inou M, Miyagawa Y, Kiyokawa N, Fujimoto J, Sato T, Umezawa A. Glycolipid dynamics in generation and differentiation of induced pluripotent stem cells. Scientific Report. 2015; 5:14988 Howell KB, McMahon JM, Carvill GL, Tambunan D, Mackay MT, Rodriguez-Casero V, Webster R, Clark D, Freeman JL, Calvert S, Olson HE, Mandelstam S, Poduri A, Mefford HC, Harvey AS, Scheffer IE. SCN2A encephalopathy: A major cause of epilepsy of infancy with migrating focal seizures. Neurology. 2015;85(11): 958-966 Ferreira LS, Pallhares D, Seguti VF, Gava M, Marasciulo ACE. Epilepsia e Previdência Social: a decisão médico-pericial. Revista Brasileira de Saúde Ocupacional 2012; 37(126):330-338 Porter R. Antiepileptic Drug Development Program1. 1984; 293-305. Lambert N, Dauve C, Ranza E, Makrythanasis P, Santoni F, Sloan-Béna F, Gimelli S, Blouin JL, Guipponi M, Bottani A, Antonarakis SE, Kosel MM, Fluss J, Paoloni-Giacobino A. Novel NEXMIF pathogenic variant in a boy with severe autisticfeatures, intellectual disability, and epilepsy, and his mildly affected mother. J Hum Genet. 2018; 63(7):847-850 Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov. 2013; 12(10): 757-776. OMIM. SMAD-SPECIFIC E3 UBIQUITIN PROTEIN LIGASE 2; SMURF2. [Internet]. [Consultado 2 Nov 2019]. Disponible en: https://www.omim.org/entry/605532?search=SMURF2&highlight=smurf2 Murillo E. Characteristics of people with the STXBP1 syndrome in Spain: Implications for diagnosis. An Pediatr. 2019; S1695-4033(19)30176-6. Gong JE, Liao HM, Long HY, Li XM, Long LL, Zhou L, Gu WP, Lu SH, Qu Q, Yang LM, Xiao B, Qu J. SCN1B and SCN2B gene variants analysis in dravet syndrome patients: Analysis of 22 cases. Medicine (Baltimore). 2019; 98(13): e14974. Lauritano A, Moutton S, Longobardi E, Tran Mau-Them F, Laudati G, Nappi P, Soldovieri MV, Ambrosino P, Cataldi M, Jouan T, Lehalle D, Maurey H, Philippe C, Miceli F, Vitobello A, Taglialatela M A novel homozygous KCNQ3 loss‐of‐ function variant causes non-syndromic intellectual disability and neonatal‐onset pharmacodependent epilepsy. Epilepsia Open.2019;4(3):464-475 Roy A, Narayan G. Oncogenic potential of nucleoporins in nonhematological cancers: recent update beyond chromosome translocation and gene fusion. J Cancer Res Clin Oncol. 2019 Pickrell WO, Lacey AS, Thomas RH, Lyons RA, Smith PEM, Rees MI. Trends in the first antiepileptic drug prescribed for epilepsy between 2000 and 2010. Seizure. 2014; 23(1):77-80. Reynolds EH, Milner G, Matthews DM, Chanarin I. ANTICONVULSANT THERAPY, MEGALOBLASTIC HAEMOPOIESIS AND FOLIC ACID METABOLISM. QJM. 1966; 35(4):521-537 Geis T, Rödl T, Topaloğlu H, Balci-Hayta B, Hinreiner S, Müller-Felber W, Schoser B, Mehraein Y, Hübner A, Zirn B, Hoopmann M, Reutter H, Mowat D, Schuierer G, Schara U, Hehr U, Kölbel H. Clinical long-time course, novel mutations and genotype-phenotype correlation in a cohort of 27 families with POMT1-related disorders. Orphanet J Rare Dis. 2019; 14(1):179-195 Castaño De La Mota C, Martín Del Valle F, Pérez Villena A, Calleja Gero ML, Losada Del Pozo R, Ruiz-Falcó ML. Hamartoma hipotalámico en la edad pediátrica: características clínicas, evolución y revisión de la literatura. Neurología.2012;27(5):268-276 Alvarez C. Farmacogenética y Farmacorresistencia en la práctica clínica Neuropediatrica: ¿En qué estamos? Chilena de epilepsia. 2012; 118-123. Krumholz A. Epilepsy: A comprehensive textbook. Annals of Neurology.1999; 45(6):825-825 OMIM. CALMODULIN 1; CALM1. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://www.omim.org/entry/114180?search=CALM1&highlight=calm1 Goldsmith D, Minassian BA. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav. 2016; 62:132-135 Lee HF, Chi CS, Tsai CR, Chen CH, Wang CC. Electroencephalographic features of patients with SCN1A-positive Dravet syndrome. Brain Drev. 2015; 37(6): 599-611 Megiddo, I., Colson, A., Chisholm, D., Dua, T., Nandi, A, Laxminarayan, R. Health and economic benefits of public financing of epilepsy treatment in India: An agentbased simulation model. Epilepsia. 2016;57(3):464-474 OMIM. CALMODULIN 1; CALM1. [Internet]. [Consultado 3 Mar 2017]. Disponible en: https://www.omim.org/entry/607416?search=chl1&highlight=chl1 Sequencing and molecular diagnostics. Análisis Genético de Epilepsia, Paneles de Secuenciación masiva. Madrid. Genetics Home Reference. Gen GRIN2A. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://ghr.nlm.nih.gov/gene/GRIN2A#normalfunction Griffin NG, Wang Y, Hulette CM, Halvorsen M, Cronin KD, Walley NM, Haglund MM, Radtke RA, Skene JH, Sinha SR, Heinzen. EL Differential gene expression in dentate granule cells in mesial temporal lobe epilepsy with and without hippocampal sclerosis. Epilepsia. 2016;57(3):376-385 McKeown L, Robinson P, Jones OT. Molecular basis of inherited calcium channelopathies: role of mutations in pore-forming subunits. Acta Pharmacol Sin. 2006;27(7):799-812 López-Laso E, Pineda M, Sans A, Velázquez R. Alternating hemiplegia of childhood: ATP1A3 gene analysis in 16 patients. Med Clinic (Bar). 2014;143(1): 25- 28 Rotaru DC, van Woerden GM, Wallaard I, Elgersma Y. Adult Ube3a Gene Reinstatement Restores the Electrophysiological Deficits of Prefrontal Cortex Layer 5 Neurons in a Mouse Model of Angelman Syndrome. J Neurosci.2018;38(37): 8011-8030 Fisher R, Cross J, French J, Higurashi N, Hirsch E, Jansen E, at al. Clasificación operacional de los tipos de cr Krumholz A. Epilepsy: A comprehensive textbook. Annals of Neurology.1999; 45(6):825-825isis por la Liga Internacional contra la Epilepsia: Documento - Posición de la Comisión para Clasificación y Terminología de la ILAE. 2017; 54 (8): 522 – 530 Deng L, Chen L, Zhao L, Xu Y, Peng X, Wang X, Ding L, Jin J, Teng H, Wang Y, Pan W, Yu F, Liao L, Li L, Ge X, Wang P. Ubiquitination of Rheb governs growth factor-induced mTORC1 activation. Cell Res. 2019; 29(2):136-150 Belvindrah R, Graus-Porta D, Goebbels S, Nave KA, Müller U. Beta1 integrins in radial glia but not in migrating neurons are essential for the formation of cell layers in the cerebral cortex. J Neurosci. 2007; 27(50):13854-65. López IM, Varela X, Marca S. Síndromes epilépticos en niños y adolescentes. REV MED CLIN CONDE. 2013; 24(6): 915-927 Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia. 2001;42(6):796-803.
dc.rights.spa.fl_str_mv	Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_f1cf
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/embargoedAccess
dc.rights.creativecommons.spa.fl_str_mv	Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)
rights_invalid_str_mv	Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales https://creativecommons.org/licenses/by-nc-sa/4.0/ Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0) http://purl.org/coar/access_right/c_f1cf
eu_rights_str_mv	embargoedAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2020
dc.publisher.faculty.spa.fl_str_mv	Facultad de Ciencias de la Salud
dc.publisher.program.spa.fl_str_mv	Medicina
institution	Universidad de Ciencias Aplicadas y Ambientales U.D.C.A
bitstream.url.fl_str_mv	https://repository.udca.edu.co/bitstreams/6dee5cea-c5b4-48f9-b7ef-e3221d829576/download https://repository.udca.edu.co/bitstreams/e0ec6dba-6871-49a5-b85e-6ff80ba562ab/download https://repository.udca.edu.co/bitstreams/93dbdaa4-08c5-433a-9bd2-693139a53446/download https://repository.udca.edu.co/bitstreams/2eb0e2a6-122b-4a46-995a-ad7a60f8ce74/download
bitstream.checksum.fl_str_mv	22622f1c50c52f74630d28c94046f79d f661acf14bedbf9f5d13897a0387e751 902d57d95d73f0d12be5c1e0a3d6f92c 156f09f353d816ba964567a079f74d08
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio - Universidad de Ciencias Aplicadas y Ambientales UDCA.
repository.mail.fl_str_mv	bdigital@metabiblioteca.com
_version_	1814213202639060992
spelling	Maradei Anaya, Silvia Juliana, dir.García Orjuela, Danilo AlejandroValbuena Mancipe, Luisa FernandaRodríguez Estupiñán, Angie TatianaTriana Buitrago, Viviana AlexandraLaguado González, Stephania2020-03-17T14:00:36Z2020-03-17T14:00:36Z2020https://repository.udca.edu.co/handle/11158/2919MH001 V14c 2020 (205924)132 páginas : gráficasEpilepsy is defined by the International League Against Epilepsy (ILAE) as a chronic disease characterized by a predisposition to the occurrence of epileptic seizures that affect around 50 million people according to WHO, with Colombia being the third largest Latin American country prevalence It is estimated that up to 40% of the different types of epilepsy are of genetic origin and gene expression may be directly or indirectly involved with neurobiological mechanisms that are responsible for therapeutic failure during the epileptogenesis process due to the interindividual variability of response to antiepileptic drugs, promoting the existence of phenotypically refractory patients and contributing to the emergence of drug resistance. This research work is a descriptive cross-sectional observational study consisting of a sample of 29 patients diagnosed with epilepsy that meets the inclusion criteria. A clinical and paraclinical characterization of the patients was carried out, and subsequently the specific genetic variants were identified to perform a bioinformatic approach through which possible target proteins and signaling pathways involved in the drug response mechanism were possible. The most frequent epilepsy was of a generalized type with 34.48% and the most frequent neurological comorbidity was the global developmental delay with 65.5%. In 20 patients, the result of the molecular study was abnormal, identifying 60 genetic variants of which 86.7%, that is, 52 variants were classified as VOUS and 36 explained the phenotype of the patients. In addition, 13.3%, that is, 8 variants, were classified as probably pathogenic variants and 7 of these explained the phenotype of the patients. Through the bioinformatic analysis of the candidate genes, create 15 biological networks, of which in 7 networks corresponding to the genes CACNA1H, CNTN2, TSC1, EPM2A, SCN1A, KCNQ3 and PRICKLE1 were found the possible devices for the response to medications and other potential therapeutic targets were proposed.La epilepsia es definida por la Liga Internacional Contra la Epilepsia (ILAE) como una enfermedad crónica que se caracteriza por una predisposición a la aparición de crisis epilépticas que afecta alrededor de 50 millones de personas según la OMS, siendo Colombia el tercer país latinoamericano con mayor prevalencia. Se estima que hasta un 40% de los distintos tipos de epilepsia son de origen genético y la expresión de genes puede estar involucrada directa o indirectamente con los mecanismos neurobiológicos que durante el proceso de epileptogénesis son responsables del fallo terapéutico gracias a la variabilidad interindividual de respuesta a fármacos antiepilépticos, promoviendo la existencia de pacientes fenotípicamente refractarios y contribuyendo con la aparición de farmacorresistencia. Este trabajo de investigación es un estudio observacional descriptivo de corte transversal que consta de una muestra de 29 pacientes diagnosticados con epilepsia que cumplían los criterios de inclusión. Se realizó una caracterización clínica y paraclínica de los pacientes, y posteriormente se identificaron variantes genéticas seleccionadas para realizar una aproximación bioinformática mediante la cual fueron propuestas posibles proteínas diana y vías de señalización involucradas en el mecanismo de respuesta a fármacos. La epilepsia más frecuente fue de tipo generalizado con un 34.48% y la comorbilidad neurológica más frecuente fue el retardo global del desarrollo con un 65.5%. En 20 pacientes el resultado del estudio molecular fue anormal, identificándose 60 variantes genéticas de las cuales un 86,7 %, es decir 52 variantes fueron clasificadas como VOUS y 36 explicaban el fenotipo de los pacientes. Adicionalmente el 13,3 % es decir 8 variantes, fueron clasificadas como variantes probablemente patogénicas y 7 de estas explicaban el fenotipo de los pacientes. A través del análisis bioinformático de los genes candidatos se crearon 15 redes biológicas, de las cuales en 7 redes correspondientes a los genes CACNA1H, CNTN2, TSC1, EPM2A, SCN1A, KCNQ3 y PRICKLE1 fueron hallados posibles mecanismos para explicar la respuesta a fármacos y se propusieron potenciales blancos terapéuticos.PregradoMédico(a) Cirujanoapplication/pdfspaBogotá : Universidad de Ciencias Aplicadas y Ambientales, 2020Facultad de Ciencias de la SaludMedicinaDerechos Reservados - Universidad de Ciencias Aplicadas y Ambientaleshttps://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/embargoedAccessAtribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)http://purl.org/coar/access_right/c_f1cfBiología ComputacionalEpilepsiaResistencia a MedicamentosConvulsionesCaracterización clínica y genética de una muestra de pacientes colombianos con Epilepsia y análisis de posibles factores moleculares intervinientes en la respuesta a fármacosTrabajo de grado - Pregradohttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesisinfo:eu-repo/semantics/publishedVersionTexthttp://purl.org/redcol/resource_type/TPhttp://purl.org/coar/version/c_970fb48d4fbd8a85Organización Mundial de la Salud. Epilepsia. Trastornos Neurologicos: desafíos para la salud Pública. Ginebra. 2006; 62 -77Organización Panamericana de la Salud, Organización mundial de la salud. Informe de la epilepsia en América Latina y el Caribe. Washington; 2013Ministerio de Salud y Protección Social [sede web]. Epilepsia: mucho más que convulsions; 2017 [ acceso 18 de julio de 2018]. Boletin de Prensa No016 de 2017. Disponible en: https://www.minsalud.gov.co/Paginas/Epilepsia-mucho-mas-queconvulsiones.aspxMedina M, Kestel D, Acevedo C, Mesa T, Rodriguez J. Epilepsia en Latino America Experiencias (OPS 2016). 2016.Maradei-Anaya SJ, Espinosa E, Izquierdo Á, Velasco-Parra HM. Detection of subtelomeric rearrangements due to MLPA in paediatric patients with refractory epilepsy in Colombia: the role of the CHL1 gene in pharmacoresistance. Rev Neurol. 2013; 57(10):444-50.Medina Malo C. Aspectos Clínicos y Psicosociales. Epilepsia. Bogotá D.C: Editorial Medica Panamericana; 2004. p39–44Schmidt D, Löscher W. New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr. 2009;9(2):47-52Gall CM, Lynch G. Integrins, synaptic plasticity and epileptogenesis. Adv Exp Med Biol. 2004; 548:12-33.Maradei Anaya SJ. Análisis de los perfiles genómicos de pacientes colombianos con Epilepsia Refractaria [Tesis de Maestría] Universidad Nacional de Colombia. 2017Maradei Anaya SJ. Detección de Rearreglos Subteloméricos por MLPA en Pacientes Pediátricos con Epilepsia Refractaria en tres centros de Referencia Nacional en Colombia [Tesis de Pregrado]. Universidad Nacional de Colombia: 2013.Megiddo I, Colson A, Chisholm D, Dua T, Nandi A. Laxminarayan R Health and economic benefits of public financing of epilepsy treatment in India: An agentbased simulation model. Epilepsia. 2016; 57(3):464-474Algahtani H, Al-Hakami F Al-Shehri M, Shirah B, Al-Qahtani MH, Abdulkareem AA, Naseer MI. A very rare form of autosomal dominant progressive myoclonus epilepsy caused by a novel variant in the PRICKLE1 gene. Seizure. 2019; 69: 133-139STRING. [Internet]. [Consultado 6 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=1qszWqvtLbTkKwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005; 46(2): 224-235.Pellegrino F. Trastornos del movimiento IV. Movimientos involuntarios originados en el Sistema Nervioso Central. Revista Argentina de Neurología Veterinaria. 2019;7(2):1Genetics Home Reference. Chromosomes & mtDNA. [Internet]. [Consultado 3 Oct 2019]. Disponible en: https://ghr.nlm.nih.gov/chromosomeGastaut H. Classification of the epilepsies: proposal for the international classification. Epilepsia 1969; 10: 514 – 521.Paolone G, Falcicchia C, Lovisari F, Kokaia M, Bell WJ, Fradet T, Barbieri M, Wahlberg LU, Emerich DF, Simonato M. Long-Term, Targeted Delivery of GDNF from Encapsulated Cells Is Neuroprotective and Reduces Seizures in the Pilocarpine Model of Epilepsy. J Neurosci. 2019; 39(11):2144-2156Barro-Soria R. Epilepsy-associated mutations in the voltage sensor of KCNQ3 affect voltage dependence of channel opening. J Gen Physiol. 2019;151(2):247-257Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-424.Jovel CAE, Pardo CM, Moreno CM, Vergara J, Hedmont D, Mejía FES. Perfil demográfico y social de la epilepsia en una población vulnerable y de bajos recursos económicos en Bogotá, Colombia. Neurología: Publicación oficial de la Sociedad Española de Neurología 2016; 31(8): 528-534Tarcas Yacubian EM, Contreas Caicedo G, Rios Pohl L.Tratamiento Farmacológico de las Epilepsias. Sao Paulo. ALADE; 2014. 35-51Asconapé JJ. Epilepsy: new drug targets and neurostimulation. Neurol Clin. 2013; 31(3): 785-798.Gavatha M, Ioannou I, Papavasiliou AS. Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav. 2011; 20(4): 691-693.Feenstra B, Pasternak B, Geller F, Carstensen L, Wang T, Huang F, Eitson JL, Hollegaard MV, Svanström H, Vestergaard M, Hougaard DM, Schoggins JW, Jan LY, Melbye M, Hviid A. Common variants associated with general and MMR vaccine-related febrile seizures. Nat Genet. 2014;46(12):1274-1282Ministerio de Salud y Protección Social. Guía de Práctica Clínica sobre el Diagnóstico y Tratamiento de la Epilepsia. Organización Panamericana de la Salud;2014Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013; 9: 883- 892.Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross H, Elger C, Enegel J, Forsgren L, Jacqueline A, Glynn M, Hesdorffer D, Lee I, Mathem G, Moshé S, Perucca E, Scheffer E, Tomson T, Watanabe M, Wiebe S. Definición Clínica Practica de la epilepsia. Epilepsia 2014; 55 (4): 475-485STRING. [Internet]. [Consultado 4 Nov 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=z6KMfceDySvUGenetics Home Reference. GLRA1 gene. [Internet]. [Consultado 30 Oct 2019]. Disponible en: https://ghr.nlm.nih.gov/gene/GLRA1Eckle VE, Shcheglovitov A, Vitko I, Dey D, Choo Yap C, Winckler B, Perez Reyes E. Mechanisms by which a CACNA1H mutation in epilepsy patients increases seizure susceptibility. J Physiol. 2014; 592.4: 795–809.Núñez E, Bonilla Y, Varela D. Actualización de métodos diagnósticos en el Complejo de Esclerosis Tuberosa. Rev Mex Neuroci. 2016; 17 (4): 86-95.Dixit AB, Banerjee J, Srivastava A, Tripathi M, Sarkar C, Kakkar A, Jain M, Chandra PS RNA-seq analysis of hippocampal tissues reveals novel candidate genes for drug refractory epilepsy in patients with MTLE-HS. Genomics. 2016;107(5):178-88STRING. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=ulsA1j1oSBWX)Sharma S, Carlson S, Puttachary S, Sarkar S, Showman L, Putra M, Kanthasamy AG, Thippeswamy T. Role of the Fyn-PKCδ signaling in SE-induced neuroinflammation and epileptogenesis in experimental models of temporal lobe epilepsy. Neurobiol Dis. 2018; 110:102-121Skluzacek JV, Watts KP, Parsy O, Wical B, Camfield P. Síndrome de Dravet y asociaciones de padres: la experiencia de la Liga IDEA con condiciones comórbidas, mortalidad, manejo, adaptación y duelo. Epilepsia. 2011; 52: 95-101Jensen AA, Mosbacher J, Elg S, Lingenhoehl K, Lohmann T, Johansen TN, et al. The anticonvulsant gabapentin (neurontin) does not act through gammaaminobutyric acid-B receptors. Mol Pharmacol 2002; 61(6):1377-1384Ip JPK, Mellios N, Sur M. Rett syndrome: insights into genetic, molecular and circuit mechanisms. Nat Rev Neurosci. 2018;19(6): 368-382Hoda JC, Wanischeck M, Bertrand D, Steinlein OK. Pleiotropic functional effects of the first epilepsy-associated mutation in the human CHRNA2 gene. FEBS Lett. 2009;OMIM. PROTEIN O-MANNOSYLTRANSFERASE 1; POMT1. [Internet]. [Consultado 3 Nov 2019]. Disponible en: https://www.omim.org/entry/607423?search=POMT1&highlight=pomt1Liu J, Tong L, Song S, Niu Y, Li J, Wu X, Zhang J, Zai CC, Luo F, Wu J, Li H, Wong AHC, Sun R, Liu F, Li B. Novel and de novo mutations in pediatric refractory epilepsy. Movel Brain. 2018;11(1): 48-66Judson MC, Wallace ML, Sidorov MS, Burette AC, Gu B, van Woerden GM, King IF, Han JE, Zylka MJ, Elgersma Y, Weinberg RJ, Philpot BD. GABAergic neuron-specific loss of Ube3a causes Angelman syndrome-like EEG abnormalities and enhances seizure susceptibility. Neuron. 2016; 90(1): 56-69Bai B, Guo YR, Zhang YH, Jin CC, Zhang JM, Chen H, Zhu BS. Novel DOCK7 mutations in a Chinese patient with early infantile epileptic encephalopathy 23. Chin Med J (Engl). 2019; 132(5): 600-603Reyes Botero G, Uribe C. Epilepsia refractaria. Acta de Neurología Colombiana. 2010; 26: 34 - 36Glass HC. Neonatal seizures: advances in mechanisms and management. Clin Perinatol. 2014; 41(1):177-190Chen ZR, Liu DT, Meng H, Liu L, Bian WJ, Liu XR, Zhu WW, He Y, Wang J, Tang B, Su T, Yi YH. Homozygous missense TPP1 mutation associated with mild late infantile neuronal ceroid lipofuscinosis and the genotype-phenotype correlation. Seizure.2019; 68:180-185Gallek MJ, Skoch J, Ansay T, Behbahani M, Mount D, Manziello A, Witte M, Bernas M, Labiner DM, Weinand MECortical gene expression: prognostic value for seizure outcome following temporal lobectomy and amygdalohippocampectomy. Neurogenetics. 2016;17(4):211-218.Stödberg T, McTague A, Ruiz AJ, Hirata H, Zhen J, Long P, Farabella I, Meyer E, Kawahara A, Vassallo G, Stivaros SM, Bjursell MK, Stranneheim H, Tigerschiöld S, Persson B, Bangash I, Das K, Hughes D, Lesko N, Lundeberg J, Scott RC, Poduri A, Scheffer IE, Smith H, Gissen P, Schorge S, Reith ME, Topf M, Kullmann DM, Harvey RJ, Wedell A, Kurian MA. Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures. Nat Commun.2015;6:8038Mirza N, Vasieva O, Marson AG, Pirmohamed M. Exploring the genomic basis of pharmacoresistance in epilepsy: an integrative analysis of large-scale gene expression profiling studies on brain tissue from epilepsy surgery. Hum Mol Genet. 2011; 20(22):4381-4394Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010; 51(4): 676-685Licourt Otero D, Cala Hernández O, Travieso Téllez A, Orraca Castillo M. La heterogeneidad genética en la epilepsia: presentación de familias. Revista de Ciencias Médicas de Pinar del Río. 2015; 19(1):141-150.Organización Panamericana de la Salud, Organización Mundial de la Salud. Estrategia y plan de acción sobre la epilepsia. 51. º Consejo Directivo de la OPS, 63.ª sesión del Comité Regional de la OMS para las Américas.2011.Huisman S, Mulder PA, Redeker E, Bader I, Bisgaard AM, Brooks A, Cereda A, Cinca C, Clark D, Cormier-Daire V, Deardorff MA, Diderich K, Elting M, van Essen A, Fitz Patrick D, Gervasini C, Gillessen-Kaesbach G, Girisha KM, Hilhorst-Hofstee Y, Hopman S, Horn D, Isrie M, Jansen S, Jespersgaard C, Kaiser FJ, Kaur M, Kleefstra T, . Krantz ID, Lakeman P, Landlust, A, Lessel D. Phenotypes and genotypes in individuals with SMC1A variants. American Journal of Medical Genetics; 173(8): 2108–2125.Bencurova P, Baloun J, Musilova K, Radova L, Tichy B, Pail M, Zeman M, Brichtova E, Hermanova M, Pospisilova S, Mraz M, Brazdil M. MicroRNA and mesial temporal lobe epilepsy with hippocampal sclerosis: Whole miRNome profiling of human hippocampus. Epilepsia. 2017; 58(10):1782-1793INVITAE [internet]. [consultado 3 Nov 2019]. Disponible en: https://www.invitae.com/en/physician/genes/20112/#info-panel-gene_functionSplawski S, Yoo DS, Stotz SC, Cherry A, Clapham DE, Keating MT. CACNA1H Mutations in Autism Spectrum Disorders. THE JOURNAL OF BIOLOGICAL CHEMISTRY. 2006; 281 (31): 22085-22091STRING. [Internet]. [Consultado 2 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=kGfzkLat0WoiValles-Ortega J, Duran J, Garcia-Rocha M, Bosch C, Saez I, Pujadas L, Serafin A, Cañas X, Soriano E, Delgado-García JM, Gruart A, Guinovart JJ. Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease. EMBO Mol Med. 2011;3(11):667-681Chen T, Giri M, Xia Z, Subedi YD, Li Y. Genetic and epigenetic mechanisms of epilepsy: a review. Neuropsychiatr Dis Treat. 2017; 13:1841-1859Jin H, Jin-Jing HL, Zhen Su H, Wang DN, Lin Y, Wang N, Chen WJ. Identification of a Novel Homozygous Splice-Site Mutation in SCARB2 that Causes Progressive Myoclonus Epilepsy with or without Renal Failure.Chin Med J (Engl). 2018; 131(13):1575-1583Roach PJ. Glycogen phosphorylation and Lafora disease. Mol ASpects Med. 2015; 46:78-84Méndez Ayala A, Nariño D, Rosselli D. Burden of epilepsy in Colombia. Neuroepidemiology. 2015; 44(3): 144-148Lopes Cendes I, Oliveria Ribero PA. Aspectos genéticos de las epilepsias: una visión actualizada. Rev Med Clinica los Condes. 2013;24(6):909-914Rogawski MA, Gryder D, Castaneda D, Yonekawa W, Banks MK, Lia H. GluR5 kainate receptors, seizures, and the amygdala. Ann N Y Acad Sci. 2003; 985:150- 162.Rozman C, Cardellach F. Medicina Interna. 18 th. Ed. Madrid: EL SERVIER; 2016:1330-1347Balestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. Neuroscience Letters. 2018; 667: 27- 39Löscher W. How to Explain Multidrug Resistance in Epilepsy? Epilepsy Currents. 2005; 5(3):107-112ILAE. EPILEPSY SYNDROMES. [Internet]. [Consultado 9 Nov 2019]. Disponible en: https://www.epilepsydiagnosis.org/syndrome/epilepsy-syndromegroupoverview.htmlSTRING. [Internet]. [Consultado 5 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=ddQnrNPJpBOSSTRING. [Internet]. [Consultado 5 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=l1b3ohYenpQzIVAME. Pruebas genéticas - Epilepsia nocturna del lóbulo frontal autosómica dominante (Autosomal dominant nocturnal frontal lobe epilepsy - ADNFLE-) – Genes CHRNA2, CHRNA4 y CHRNB2. – IVAMI. [internet] [consultado 4 Nov 2019] Disponible en: https://www.ivami.com/es/pruebas-geneticasmutaciones-de-genes-humanos-enfermedades-neoplasias-yfarmacogenetica/1371-pruebas-geneticas-epilepsia-nocturna-del-lobulo-frontal-autosomica-dominante-autosomal-dominant-nocturnal-frontal-lobe-epilepsy-adnflegenes-i-chrna2-chrna4-i-y-i-chrnb2Makrythanasis P, Kato M, Zaki M, Saitsu H, Nakamura K, Santoni F. Pathogenic Variants in PIGG Cause Intellectual Disability with Seizures and Hypotonia. The American Journal of Human Genetics. 2016;98(4):615-626.Hosford DA, Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia. 1997; 38(4):408-414.Nazish HR, Ali N, Ullah S.The possible effect of SCN1A and SCN2A genetic variants on carbamazepine response among Khyber Pakhtunkhwa epileptic patients, Pakistan. Ther Clin Risk Manag. 2018;14: 2305-2313Espinosa C, Sobrino FE. Farmacorresistencia en epilepsia. Conceptos clínicos y neurobiológicos. Neurología; 2015: 385 395.Liu Y, Guo Y, Liu P, Li F, Yang C, Song J, Hu J, Xin D, Chen Z. A case of Pitt-Hopkins Syndrome with de novo mutation in TCF4: Clinical features and treatment for epilepsy. IntJ Dev Neurosci. 2018; 67:51-54Goldensohn ES, Porter RJ, Schwartzkroin PA. The American Epilepsy Society: an historic perspective on 50 years of advances in research. Epilepsia. 1997; 38(1):124-150.Ortiz L, Tabak N. Farmacogenómica en la práctica clínica. Rev Med Clin Condes. 2012; 23(5): 616-621.León Sarmiento FE. Estudio neuroepidemiológico nacional (EPINEURO) colombiano. Revista Panamericana de Salud Pública. 2003; 14(2):104-111.Paciorkowski AR, McDaniel SS, Jansen LA, Tully H, Tuttle E, Ghoneim DH, Tupal S, Gunter SA, Vasta V, Zhang Q, Tran T, Liu YB, Ozelius LJ, Brashear A, Sweadner KJ, Dobyns WB, Hahn S. Novel mutations in ATP1A3 associated with catastrophic early life epilepsy, episodic prolonged apnea, and postnatal microcephaly. Epilepsia. 2015; 56(3):422-430OMIM. MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 7; SMAD7. [Internet]. [Consultado 2 Nov 2019]. Disponible en: https://www.omim.org/entry/602932?search=SMAD7&highlight=smad7Schubert-Bast S, Rosenow F, Klein KM, Reif PS, Kieslich M, Strzelczyk A. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspective. Epilepsy Behav. 2019; 91:94-98.Marson, Anthony G, Al-Kharusi, Asya M, Alwaidh, Muna, Appleton Richard, Baker, Gus A,Chadwick. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007; 369(9566):1016-1026Liu J, Schenker M, Ghiasvand S, Berdichevsky Y. Kinase Inhibitors with Antiepileptic Properties Identified with a Novel in Vitro Screening Platform. Int J Mol Sci. 2019;20(10)Tanaka AJ, Cho MT, Millan F, Juusola J, Retterer K, Joshi C, Niyazov D, Garnica A, Gratz E, Deardorff M, Wilkins A, Ortiz-Gonzalez X, Mathews K, Panzer K, Brilstra E, van Gassen KL, Volker-Touw CM, van Binsbergen E, Sobreira N, Hamosh A, McKnight D, Monaghan KG, Chung WK. Mutations in SPATA5 Are Associated with Microcephaly, Intellectual Disability, Seizures, and Hearing Loss. Am J Hum Genet. 2015; 97(3): 457.464National Center for Advancing Translational Sciences. Hiperekplexia hereditaria. [Internet]. [Consultado 30 Oct 2019]. Disponible en: https://rarediseases.info.nih.gov/espanol/12005/hiperekplexiahereditaria/cases/66561Ortega Moreno L, Giráldez BG, Verdú A, García Campos O, Sánchez Martín G, Serratosa JM, Guerrero López R. Nueva mutación en el gen STXBP1 en un paciente con síndrome de Ohtahara no lesional. Neurologia. 2016; 31(8): 523-527STRING. [Internet]. [Consultado 30 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=7B88K6sTJMrYHardies K, Cai Y, Jardel C, Jansen AC, Cao M, May P, Djémié T, Hachon Le Camus C, Keymolen K, Deconinck T, Bhambhani V, Long C, Sajan SA, Helbig KL; AR working group of the EuroEPINOMICS RES Consortium, Suls A, Balling R, Helbig I, De Jonghe P, Depienne C, De Camilli P, Weckhuysen S. Loss of SYNJ1 dual phosphatase activity leads to early onset refractory seizures and progressive neurological decline. Brain. 2016; 139(9):2420-2430Sell K, Storch K, Hahn G, Lee-Kirsch MA, Ramantani G, Jackson S, Neilson D, von der Hagen M, Hehr U, Hehr U, Smitka M. Variable clinical course in acute necrotizing encephalopathy and identification of a novel RANBP2 mutation. Brain&Development. 2016: 38(8): 777-780Vidaurre J. Síndromes epilépticos genéticos. Pediátr Panamá. 2017; 46 (2): 68STRING. [Internet]. [Consultado 2 Nov 2019]. https://stringdb.org/cgi/network.pl?taskId=rOMfYUeidfAcBalestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. Neurosci Lett. 2018; 667: 27-39.Izquierdo AY. Crisis convulsivas. Concepto, clasificación y etiología. Emergencias: Revista de la Sociedad Española de Medicina de Urgencias y Emergencias. 2005; 17(5):1068-1073.Rossetti AO, Jeckelmann S, Novy J, Roth P, Weller M, Stupp R. Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro-oncology 2014; 16(4):584-588.Niday Z, Hawkins VE, Soh H, Mulkey DK, Tzingounis AV. EpilepsyAssociated KCNQ2 Channels Regulate Multiple Intrinsic Properties of Layer 2/3 Pyramidal Neurons. J Neurosci. 2017;37(3):576-586Silbergleit R, Lowenstein D, Durkalski V, Conwit R. Lessons from the RAMPART study--and which is the best route of administration of benzodiazepines in status epilepticus. Epilepsia. 2013; 54 Suppl 6:74-77Koemans TS, Kleefstra T, Chubak MC, Stone MH, Reijnders MRF, de Munnik S, Willemsen MH, Fenckova M, Stumpel CTRM, Bok LA, Sifuentes Saenz M, Byerly KA, Baughn LB, Stegmann APA, Pfundt R, Zhou H, van Bokhoven H, Schenck A, Kramer JM. Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intelectual disability and autism spectrum disorder. PLoS Genet. 2017;13(10)Scott DF. The discovery of anti-epileptic drugs. J Hist Neurosci.1992;1(2):111-118.Lu Z, Reddy MV, Liu J, Kalichava A, Liu J, Zhang L, Chen F, Wang Y, Holthauzen LM, White MA, Seshadrinathan S, Zhong X, Ren G, Rudenko G. Molecular Architecture of Contactin-associated Protein-like 2 (CNTNAP2) and Its Interaction with Contactin 2 (CNTN2). J Biol Chem. 2016;291(46):24133-24147STRING. [Internet]. [Consultado 2 Nov 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=OE9wU0lV0paLMingarro Castillo MM, Carmona de la Morena J, Latre Martínez P, Aras Portilla LM. Síndrome de Dravet. Rev Clin Med Fam. 2014; 7 (2): 134 -136STRING. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=AnkpHPOhkou6Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 2001; 21(8):904-919.UniProt. UniProtKB - P78352 (DLG4_HUMAN). [Internet]. [Consultado 2 Nov 2019]. Disponible en: https://www.uniprot.org/uniprot/P78352Hosford DA, Clark S, Cao Z, Wilson WA, Lin FH, Morrisett RA, et al. The role of GABAB receptor activation in absence seizures of lethargic (lh/lh) mice. Science.1992; 257(5068):398-401.STRING. [Internet]. [Consultado 4 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=1ziRpo3Vx8nSKuersten M, Tacke M, Gerstl L, Hoelz H, Stülpnagel CV, Borggraefe I. Antiepileptic therapy approaches in KCNQ2 related epilepsy: A systematic review. Eur J Med Genet. 2019; S1769-7212(18)30663-3.Arzimanoglou AA, Dumas C, Ghirardi L. Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. French Neurologists Sabril Study Group. Seizure 1997; 6(3):225-231.Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des. 2004; 10(12):1295-1312.Fry AE, Rees E, Thompson R, Mantripragada K, Blake P, Jones G, Morgan S, Jose S, Mugalaasi H, Archer H, McCann E, Clarke A, Taylor C, Davies S, Gibbon F, Te Water Naude J, Hartley L, Thomas G, White C, Natarajan J, Thomas RH, Drew C, Chung SK, Rees MI, Holmans P, Owen MJ, Kirov G, Pilz DT, Kerr MP. Pathogenic copy number variants and SCN1A mutations in patients with intellectual disability and childhood-onset epilepsy. BMC Med Genet. 2016; 17(1):34Wright AG, Demyanenko GP, Powell A, Schachner M, Enriquez-Barreto L, Tran TS, Polleux F, Maness PF. Close homolog of L1 and neuropilin 1 mediate guidance of thalamocortical axons at the ventral telencephalon. J Neurosci. 2007; 27(50):13667-13679.Bisulli F, Muccioli L, d'Orsi G, Canafoglia L, Freri E, Licchetta L, Mostacci B, Riguzzi P, Pondrelli F, Avolio C, Martino T, Michelucci R, Tinuper P. Treatment with metformin in twelve patients with Lafora disease. Orphanet J Rare Dis. 2019;14(1):149.Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel J. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46(4): 470-472STRING. [Internet]. [Consultado 5 Oct 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=7oQo0Tl0gF1WAndreyeva A, Leshchyns'ka I, Knepper M, Betzel C, Redecke L, Sytnyk V, Schachner M. CHL1 is a selective organizar of the presynaptic machinery chaperoning the SNARE complex. PLoS One. 2010; 5(8):e12018Serrano Barrera OR. Bioinformática: una brecha en la formación en el Sistema Nacional de Salud. Revista Cubana de Educación Media Superior; 26(1): 121-135Hermann BP, Seidenberg M, Dow C, Jones J, Rutecki P, Bhattacharya A. Cognitive prognosis in chronic temporal lobe epilepsy. Ann Neurol. 2006; 60(1):80- 87.Dyment DA, Smith AC, Humphreys P, Schwartzentruber J, Beaulieu CL; FORGE Canada Consortium, Bulman DE, Majewski J, Woulfe J, Michaud J, Boycott KM. Homozygous nonsense mutation in SYNJ1 associated with intractable epilepsy and tau pathology. Neurobiol Aging. 2015;36(2);1222e1-1222e5Kong Q, Min X, Sun R, Gao J, Liang R, Li L, Chu X. Effects of pharmacological treatments on hippocampal NCAM1 and ERK2 expression in epileptic rats with cognitive dysfunction. Oncol Lett. 2016;12(3):1783-1791Ikemoto S, Hamano SI, Hirata Y, Matsuura R, Koichihara R. Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years. Seizure. 2019; S1059-1311(19):30136-0Tijssen MA, Rees M. Hyperekplexia. GeneReviews. 2007.Oguni H, Nishikawa A, Satoa Y, Otania Y, Itoa S, Nagataa S, Katob M, Hamanakac K, Miyatake S, Matsumotoc N. A missense variant of SMC1A causes periodic pharmaco-resistant cluster seizures similar to PCDH19-related epilepsy. Epilepsy Research. 2019; 15: 106149Bakir-Gungor B, Baykan B, Ugur İseri S, Tuncer FN, Sezerman OU. Identifying SNP targeted pathways in partial epilepsies with genome-wide association study data. Epilepsy Res. 2013; 105(1-2):92-102.Forsgren L, Hauser WA, Olafsson E, Sander, JS, Sillanpää M, Tomson T. Mortality of epilepsy in developed countries: a review. Epilepsia. 2005; 46 (11):18-27.Capovilla G, Beccaria F, Beghi E, Minicucci F, Sartori S, Vecchi M. Treatment of convulsive status epilepticus in childhood: recommendations of the Italian League Against Epilepsy. Epilepsia. 2013; 54 Suppl 7:23-34Perrault I, Hamdan FF, Rio M, Capo-Chichi JM, Boddaert N, Décarie JC, Maranda B, Nabbout R, Sylvain M, Lortie A, Roux PP, Rossignol E, Gérard X, Barcia G, Berquin P, Munnich A, Rouleau GA, Kaplan J, Rozet JM, Michaud JL. Mutations in DOCK7 in individuals with epileptic encephalopathy and cortical blindness. Am J Hum Genet. 2014;94(6):891-897Yelam A, Nagarajan E, Chuquilin M, Govindarajan R. Leucoencephalopathy with brain stem and spinal cord involvement and lactate elevation: a novel mutation in the DARS2 gene. BMJ Case Rep. 2019;12(1)Gastaut H, Naquet R, Poire R, Tassinari CA. TREATMENT OF STATUS EPILEPTICUS WITH DIAZEPAM (VALIUM). Epilepsia 1965; 6:167-182García Morales I. Limitaciones en el tratamiento de la Epilepsia. Neurología. 2016;31(1):3-8Anwar A, Saleem S, Patel UK, Arumaithurai K, Malik P. Síndrome de Dravet: una visión general. Cureus. 2019; 11 (6): e5006.Cendes F, Theodore WH, H. Brinkmann BH, Sulc V, Cascino GD. Neuroimaging of epilepsy. Handb Clin Neurol. 2016; 136: 985–1014.STRING. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=LwWuyKVegPwTBurneo JG, Tellez-Zenteno J, Wiebe S. Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence. Epilepsy. 2006; 66(1-3):63-74.Nakamura K, Osaka H, Murakami Y, Anzai R, Nishiyama K, Kodera H, Nakashima M, Tsurusaki Y, Miyake N, Kinoshita T, Matsumoto N, Saitsu H. PIGO mutations in intractable epilepsy and severe developmental delay with mild elevation of alkaline phosphatase levels. Epilepsia. 2014; 55(2): 13-17Gu B, Carstens KE, Judson MC, Dalton KA, Rougié M, Clark EP, Dudek SM, Philpot BD. Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice. J Clin Invest; 129(1): 163-168Scherpenzeel MV, Timal S, Rymen D, HoischenA, Wuhrer M , Hipgrave-Ederveen A, Grunewald S, Peanne R, Saada A, Edvardson S, Grønborg S, Ruijter G, Kattentidt-Mouravieva A, Moritz Brum J, Freckmann ML, Tomkins S, Jalan A, Prochazkova D, Ondruskova N, Hansikova H, Willemsen MA, Hensbergen PJ, Matthijs G, Wevers RA, Veltman JA, Morava E, Lefeber DJ. Diagnostic serum glycosylation profile in patients with intellectual disability as a result of MAN1B1 deficiency. Brain. 2014; 137: 1030–1038van Diepen L, Buettner FFR, Hoffmann D, Thiesler CT, von Bohlen Und Halbach O, von Bohlen Und Halbach V, Jensen LR, Steinemann D, Edvardson S, Elpeleg O, Schambach A, Gerardy-Schahn R, Kuss AW. A patient-specific induced pluripotent stem cell model for West syndrome caused by ST3GAL3 deficiency. Eur J Hum Genet. 2018; 26(12):1773-1783Bode A, Lynch JW. The impact of human hyperekplexia mutations on glycine receptor structure and function. Mol Brain. 2014; 7:2Nguyen TT, Murakami Y, Sheridan E, Ehresmann S, Rousseau J, St-Denis A, Chai G, Ajeawung NF, Fairbrother L, Reimschisel T, Bateman A, Berry-Kravis E, Xia F, Tardif J, Parry DA, Logan CV, Diggle C, Bennett CP, Hattingh L, Rosenfeld JA, Perry MS, Parker MJ, Le Deist F, Zaki MS, Ignatius E, Isohanni P, Lönnqvist T, Carroll CJ, Johnson CA, Gleeson JG, Kinoshita T, CampeauPM. Mutations in GPAA1, Encoding a GPI Transamidase Complex Protein, Cause Dev elopmental Delay, Epilepsy, Cerebellar Atrophy, and Osteopenia. Am J Hum Genet. 2017; 101(5):856-865Irintchev A, Koch M, Needham LK, Maness P, Schachner M. Impairment of sensorimotor gating in mice deficient in the cell adhesion molecule L1 or its close homologue, CHL1. Brain Res. 2004; 1029(1):131- 134.Villamizar Schiller I, Espinosa García E. Factores de Riesgo para Epilepsia después de una Primera Crisis no Provocada en la Edad Pediátrica en el Hospital Militar Central (2005-2008). 2010Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BA. Lafora disease - from pathogenesis to treatment strategies. Nat Rev Neurol. 2018;14(10):606-617Löscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver ways out of the current dilemma. Epilepsia 2011; 52(4):657-678Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41 (1):3-9Baulac S. mTOR signaling pathway genes in focal epilepsy. 2016. Prog Brain Res; 226: 61-79Patrizio A, Renner M, Pizzarelli R, Triller A, Specht CG. Alpha subunitdependent glycine receptor clustering and regulation of synaptic receptor numbers. Sci Rep. 2017; 7: 10899Veeramah KR, Johnstone L, Karafet TM, Wolf D, Sprissler R, Salogiannis J, Barth-Maron A, Greenberg ME, Stuhlmann T, Weinert S, Jentsch TJ, Pazzi M, Restifo LL, Talwar D, Erickson RP, Hammer MF. Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. Epilepsia. 2013: 54(7); 1270-1281Puusepp S, Kovacs-Nagy R, Alhaddad B, Braunisch M, Hoffmann GF, Kotzaeridou U, Lichvarova L, Liiv M, Makowski C, Mandel M, Meitinger T, Pajusalu S, Rodenburg RJ, Safiulina D, Strom TM, Talvik I, Vaarmann A, Wilson C, Kaasik A, Haack TB, Õunap K. Compound heterozygous SPATA5 variants in four families and functional studies of SPATA5 deficiency. Eur J Hum Genet. 2018;26(3):407- 419López González FJ, Rodríguez Osorio X, Gil-Nagel Rein A, Carreño Martínez M, Serratosa Fernández J, Villanueva Haba V. Epilepsia resistente a fármacos. Concepto y alternativas terapéuticas. Neurología. 2015; 30(7): 439-446Herring BE, Nicoll RA. Long-Term Potentiation: From CaMKII to AMPA Receptor Trafficking. Annu Rev Physiol. 2016; 78:351-365Gene Cards. CHL1 gene. [Internet]. [Consultado 27 Feb 2017]. Disponible en: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CHL1Citraro R, Leo A, Santoro M, D'agostino G, Constanti A, Russo E. Role of histone deacetylases (HDACs) in epilepsy and epileptogenesis. Curr Pharm Des. 2017;23(37):5546-5562Saldaña AM, Sánchez J, Márquez DD. Farmacogenética y metabolismo de fármacos antiepilépticos: implicación de variantes genéticas en citocromos P450. Neurología.com. 2018. 50(9).Núñez E, Bonilla Y, Varela D. Actualización de métodos diagnósticos en el Complejo de Esclerosis Tuberosa. Rev Mex Neuroci. 2016; 17 (4): 86-95.McCallum AP, Gallek MJ, Ramey W, Manziello A, Witte MH, Bernas MJ, Labiner DM, Weinand ME. Cortical gene expression correlates of temporal lobe epileptogenicity. Pathophysiology. 2016;23(3):181-90.Glauser TA, Holland K, O'Brien VP, Keddache M, Martin LJ, Clark PO, Cnaan A, Dlugos D, Hirtz DG, Shinnar S, Grabowski G. Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy. Ann Neurol. 2017;81(3):444-453Panayiotopoulos CP. A Clinical Guide to Epileptic Syndromes and their Treatment .2da ed. Springer; 2010. p 91-134Koene LMC van Grondelle SE, Proietti Onori M, Wallaard I, Kooijman NHRM, van Oort A, Schreiber J, Elgersma Y. Effects of antiepileptic drugs in a new TSC/mTOR-dependent epilepsy mouse model. Ann Clin Transl Neurol. 2019;6(7):1273-1291McDaniel SS, Wong M. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. Neurosci Lett. 2011; 497(3):231- 139Klepper J. Glucose transporter deficiency syndrome (GLUT1DS) and the ketogenic diet. Epilepsia. 2008;49(8):46-49Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S1, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58(4):512-521Dey A, Kang X, Qiu J, Du Y, Jiang J. Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside. Trends Pharmacol Sci. 2016;37(6):463-484Santillán Garzón S, Álvarez D, Buades C, Romera-López A, Pérez-Cabornero L, Valero-Hervás D, et al. DIAGNÓSTICO MOLECULAR DE ENFERMEDADES GENÉTICAS: DEL DIAGNÓSTICO GENÉTICO AL DIAGNÓSTICO GENÓMICO CON LA SECUENCIACIÓN MASIVA. Rev Med Clin Condes. 2015; 26(4): 458-469OMIM. DISCOS GRANDES ANÁLISIS MAGUK 3 PROTEÍNA; DLG3. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://www.omim.org/entry/300189Ben-Shalom R, Keeshen CM, Berrios KN, An JY, Sanders SJ, Bender KJ. Opposing Effects on NaV1.2 Function Underlie Differences Between SCN2A Variants Observed in Individuals With Autism Spectrum Disorder or Infantile Seizures. Biol Psychiatry. 2017; 82(3): 224-232Démurger F, Ichkou A, Mougou-Zerelli S, Le Merrer M, Goudefroye G, Delezoide AL, Quélin C, Manouvrier S, Baujat G, Fradin M, Pasquier L, Megarbané A, Faivre L, Baumann C, Nampoothiri S, Roume J, Isidor B, Lacombe D, Delrue MA, Mercier S, Philip N, Schaefer E, Holder M, Krause A, Laffargue F, Sinico M, Amram D, André G, Liquier A, Rossi M, Amiel J, Giuliano F, Boute O, DieuxCoeslier A, Jacquemont ML, Afenjar A, Van Maldergem L, Lackmy-Port-Lis M, Vincent-Delorme C, Chauvet ML, Cormier-Daire V, Devisme L, Geneviève D, Munnich A, Viot G, Raoul O, Romana S, Gonzales M, Encha-Razavi F, Odent S, Vekemans M, Attie-Bitach T New insights into genotype-phenotype correlation for GLI3 mutations. Eur J Hum Genet. 2015; 23(1): 92-102Yurchenco PD, McKee KK, Reinhard JR, Ruegg MA. Laminin-defcient muscular dystrophy: Molecular pathogenesis and structural repair strategies. Matrix Biol. 2018: 174-187Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51(6): 1069- 1077.Hartman AL, Rubenstein JE, Kossoff EH. Intermittent fasting: a "new" historical strategy for controlling seizures? Epilepsy. 2013; 104(3):275Alexopoulos A. Pharmacoresistant epilepsy: Definition and explanation. Epileptology. 2013; 1: 38–42.Genetics Home Reference. SPATA5 gene. [Internet]. [Consultado 30 Oct 2019]. Disponible en: https://ghr.nlm.nih.gov/gene/SPATA5STRING. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://stringdb.org/cgi/network.pl?taskId=BxMbc92rLHq6Dominges F, Köning E, Schwienbacher C, Volpato CB, Picard A, Cantaloni C, Mascalzoni D, Lackner P, Heimbach A, Hoffmann P, Stanzial F, Hicks S, Parmeggiani L, Benedicenti F, Pellegrin S, Casara G, Prmastaller P. Compound heterozygous SZT2 mutations in two siblings with early-onset epilepsy, intellectual disability and macrocephaly. Seizure.2019; 66: 81-85Blanco Lago R. Estudio en la cohorte española de pacientes con síndrome de Wolf Hirschhorn: análisis de la epilepsia en el síndrome y correlación genotipofenotipo. Universidad de Oviedo. 2016.Ojima T, Shibita E, Saito S, Toyoda M, Nakajima H, Yamazaki-Inou M, Miyagawa Y, Kiyokawa N, Fujimoto J, Sato T, Umezawa A. Glycolipid dynamics in generation and differentiation of induced pluripotent stem cells. Scientific Report. 2015; 5:14988Howell KB, McMahon JM, Carvill GL, Tambunan D, Mackay MT, Rodriguez-Casero V, Webster R, Clark D, Freeman JL, Calvert S, Olson HE, Mandelstam S, Poduri A, Mefford HC, Harvey AS, Scheffer IE. SCN2A encephalopathy: A major cause of epilepsy of infancy with migrating focal seizures. Neurology. 2015;85(11): 958-966Ferreira LS, Pallhares D, Seguti VF, Gava M, Marasciulo ACE. Epilepsia e Previdência Social: a decisão médico-pericial. Revista Brasileira de Saúde Ocupacional 2012; 37(126):330-338Porter R. Antiepileptic Drug Development Program1. 1984; 293-305.Lambert N, Dauve C, Ranza E, Makrythanasis P, Santoni F, Sloan-Béna F, Gimelli S, Blouin JL, Guipponi M, Bottani A, Antonarakis SE, Kosel MM, Fluss J, Paoloni-Giacobino A. Novel NEXMIF pathogenic variant in a boy with severe autisticfeatures, intellectual disability, and epilepsy, and his mildly affected mother. J Hum Genet. 2018; 63(7):847-850Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov. 2013; 12(10): 757-776.OMIM. SMAD-SPECIFIC E3 UBIQUITIN PROTEIN LIGASE 2; SMURF2. [Internet]. [Consultado 2 Nov 2019]. Disponible en: https://www.omim.org/entry/605532?search=SMURF2&highlight=smurf2Murillo E. Characteristics of people with the STXBP1 syndrome in Spain: Implications for diagnosis. An Pediatr. 2019; S1695-4033(19)30176-6.Gong JE, Liao HM, Long HY, Li XM, Long LL, Zhou L, Gu WP, Lu SH, Qu Q, Yang LM, Xiao B, Qu J. SCN1B and SCN2B gene variants analysis in dravet syndrome patients: Analysis of 22 cases. Medicine (Baltimore). 2019; 98(13): e14974.Lauritano A, Moutton S, Longobardi E, Tran Mau-Them F, Laudati G, Nappi P, Soldovieri MV, Ambrosino P, Cataldi M, Jouan T, Lehalle D, Maurey H, Philippe C, Miceli F, Vitobello A, Taglialatela M A novel homozygous KCNQ3 loss‐of‐ function variant causes non-syndromic intellectual disability and neonatal‐onset pharmacodependent epilepsy. Epilepsia Open.2019;4(3):464-475Roy A, Narayan G. Oncogenic potential of nucleoporins in nonhematological cancers: recent update beyond chromosome translocation and gene fusion. J Cancer Res Clin Oncol. 2019Pickrell WO, Lacey AS, Thomas RH, Lyons RA, Smith PEM, Rees MI. Trends in the first antiepileptic drug prescribed for epilepsy between 2000 and 2010. Seizure. 2014; 23(1):77-80.Reynolds EH, Milner G, Matthews DM, Chanarin I. ANTICONVULSANT THERAPY, MEGALOBLASTIC HAEMOPOIESIS AND FOLIC ACID METABOLISM. QJM. 1966; 35(4):521-537Geis T, Rödl T, Topaloğlu H, Balci-Hayta B, Hinreiner S, Müller-Felber W, Schoser B, Mehraein Y, Hübner A, Zirn B, Hoopmann M, Reutter H, Mowat D, Schuierer G, Schara U, Hehr U, Kölbel H. Clinical long-time course, novel mutations and genotype-phenotype correlation in a cohort of 27 families with POMT1-related disorders. Orphanet J Rare Dis. 2019; 14(1):179-195Castaño De La Mota C, Martín Del Valle F, Pérez Villena A, Calleja Gero ML, Losada Del Pozo R, Ruiz-Falcó ML. Hamartoma hipotalámico en la edad pediátrica: características clínicas, evolución y revisión de la literatura. Neurología.2012;27(5):268-276Alvarez C. Farmacogenética y Farmacorresistencia en la práctica clínica Neuropediatrica: ¿En qué estamos? Chilena de epilepsia. 2012; 118-123.Krumholz A. Epilepsy: A comprehensive textbook. Annals of Neurology.1999; 45(6):825-825OMIM. CALMODULIN 1; CALM1. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://www.omim.org/entry/114180?search=CALM1&highlight=calm1Goldsmith D, Minassian BA. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav. 2016; 62:132-135Lee HF, Chi CS, Tsai CR, Chen CH, Wang CC. Electroencephalographic features of patients with SCN1A-positive Dravet syndrome. Brain Drev. 2015; 37(6): 599-611Megiddo, I., Colson, A., Chisholm, D., Dua, T., Nandi, A, Laxminarayan, R. Health and economic benefits of public financing of epilepsy treatment in India: An agentbased simulation model. Epilepsia. 2016;57(3):464-474OMIM. CALMODULIN 1; CALM1. [Internet]. [Consultado 3 Mar 2017]. Disponible en: https://www.omim.org/entry/607416?search=chl1&highlight=chl1Sequencing and molecular diagnostics. Análisis Genético de Epilepsia, Paneles de Secuenciación masiva. Madrid.Genetics Home Reference. Gen GRIN2A. [Internet]. [Consultado 1 Nov 2019]. Disponible en: https://ghr.nlm.nih.gov/gene/GRIN2A#normalfunctionGriffin NG, Wang Y, Hulette CM, Halvorsen M, Cronin KD, Walley NM, Haglund MM, Radtke RA, Skene JH, Sinha SR, Heinzen. EL Differential gene expression in dentate granule cells in mesial temporal lobe epilepsy with and without hippocampal sclerosis. Epilepsia. 2016;57(3):376-385McKeown L, Robinson P, Jones OT. Molecular basis of inherited calcium channelopathies: role of mutations in pore-forming subunits. Acta Pharmacol Sin. 2006;27(7):799-812López-Laso E, Pineda M, Sans A, Velázquez R. Alternating hemiplegia of childhood: ATP1A3 gene analysis in 16 patients. Med Clinic (Bar). 2014;143(1): 25- 28Rotaru DC, van Woerden GM, Wallaard I, Elgersma Y. Adult Ube3a Gene Reinstatement Restores the Electrophysiological Deficits of Prefrontal Cortex Layer 5 Neurons in a Mouse Model of Angelman Syndrome. J Neurosci.2018;38(37): 8011-8030Fisher R, Cross J, French J, Higurashi N, Hirsch E, Jansen E, at al. Clasificación operacional de los tipos de cr Krumholz A. Epilepsy: A comprehensive textbook. Annals of Neurology.1999; 45(6):825-825isis por la Liga Internacional contra la Epilepsia: Documento - Posición de la Comisión para Clasificación y Terminología de la ILAE. 2017; 54 (8): 522 – 530Deng L, Chen L, Zhao L, Xu Y, Peng X, Wang X, Ding L, Jin J, Teng H, Wang Y, Pan W, Yu F, Liao L, Li L, Ge X, Wang P. Ubiquitination of Rheb governs growth factor-induced mTORC1 activation. Cell Res. 2019; 29(2):136-150Belvindrah R, Graus-Porta D, Goebbels S, Nave KA, Müller U. Beta1 integrins in radial glia but not in migrating neurons are essential for the formation of cell layers in the cerebral cortex. J Neurosci. 2007; 27(50):13854-65.López IM, Varela X, Marca S. Síndromes epilépticos en niños y adolescentes. REV MED CLIN CONDE. 2013; 24(6): 915-927Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia. 2001;42(6):796-803.PublicationORIGINALPROYECTO UDCA-FINAL EPILEPSIA.pdfPROYECTO UDCA-FINAL EPILEPSIA.pdfapplication/pdf2701509https://repository.udca.edu.co/bitstreams/6dee5cea-c5b4-48f9-b7ef-e3221d829576/download22622f1c50c52f74630d28c94046f79dMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-814775https://repository.udca.edu.co/bitstreams/e0ec6dba-6871-49a5-b85e-6ff80ba562ab/downloadf661acf14bedbf9f5d13897a0387e751MD52TEXTPROYECTO UDCA-FINAL EPILEPSIA.pdf.txtPROYECTO UDCA-FINAL EPILEPSIA.pdf.txtExtracted texttext/plain300208https://repository.udca.edu.co/bitstreams/93dbdaa4-08c5-433a-9bd2-693139a53446/download902d57d95d73f0d12be5c1e0a3d6f92cMD53THUMBNAILPROYECTO UDCA-FINAL EPILEPSIA.pdf.jpgPROYECTO UDCA-FINAL EPILEPSIA.pdf.jpgGenerated Thumbnailimage/jpeg4177https://repository.udca.edu.co/bitstreams/2eb0e2a6-122b-4a46-995a-ad7a60f8ce74/download156f09f353d816ba964567a079f74d08MD5411158/2919oai:repository.udca.edu.co:11158/29192024-05-09 14:20:29.588https://creativecommons.org/licenses/by-nc-sa/4.0/Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientalesrestrictedhttps://repository.udca.edu.coRepositorio - Universidad de Ciencias Aplicadas y Ambientales UDCA.bdigital@metabiblioteca.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

Caracterización clínica y genética de una muestra de pacientes colombianos con Epilepsia y análisis de posibles factores moleculares intervinientes en la respuesta a fármacos

Publicaciones similares